Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

STEVEN ROSENBERG

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Anatomy

Living Beings

Procedures

Physiology

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Peng P D; Cohen C J; Yang S; Hsu C; Jones S; Zhao Y; Zheng Z; Rosenberg S A; Morgan R A
Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.
Klapper Jacob A; Thomasian Armen A; Smith Douglas M; Gorgas Gayle C; Wunderlich John R; Smith Franz O; Hampson Brian S; Rosenberg Steven A; Dudley Mark E
Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy.
Yeh Steven; Karne Neel K; Kerkar Sid P; Heller Charles K; Palmer Douglas C; Johnson Laura A; Li Zhuqing; Bishop Rachel J; Wong Wai T; Sherry Richard M; Yang James C; Dudley Mark E; Restifo Nicholas P; Rosenberg Steven A; Nussenblatt Robert B
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of STEVEN ROSENBERG (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Peng P D; Cohen C J; Yang S; Hsu C; Jones S; Zhao Y; Zheng Z; Rosenberg S A; Morgan R A
Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.
Gene therapy 2009;16(8):1042-9.
2009: Klapper Jacob A; Thomasian Armen A; Smith Douglas M; Gorgas Gayle C; Wunderlich John R; Smith Franz O; Hampson Brian S; Rosenberg Steven A; Dudley Mark E
Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy.
Journal of immunological methods 2009;345(1-2):90-9.
2009: Yeh Steven; Karne Neel K; Kerkar Sid P; Heller Charles K; Palmer Douglas C; Johnson Laura A; Li Zhuqing; Bishop Rachel J; Wong Wai T; Sherry Richard M; Yang James C; Dudley Mark E; Restifo Nicholas P; Rosenberg Steven A; Nussenblatt Robert B
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
Ophthalmology 2009;116(5):981-989.e1.
2009: Palavalli Lavanya H; Prickett Todd D; Wunderlich John R; Wei Xiaomu; Burrell Allison S; Porter-Gill Patricia; Davis Sean; Wang Chenwei; Cronin Julia C; Agrawal Neena S; Lin Jimmy C; Westbroek Wendy; Hoogstraten-Miller Shelley; Molinolo Alfredo A; Fetsch Patricia; Filie Armando C; O'Connell Michael P; Banister Carolyn E; Howard Jason D; Buckhaults Phillip; Weeraratna Ashani T; Brody Lawrence C; Rosenberg Steven A; Samuels Yardena
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma.
Nature genetics 2009;41(5):518-20.
2009: Rosenberg Steven A; Dudley Mark E
Adoptive cell therapy for the treatment of patients with metastatic melanoma.
Current opinion in immunology 2009;21(2):233-40.
2009: Wargo Jennifer A; Robbins Paul F; Li Yong; Zhao Yangbing; El-Gamil Mona; Caragacianu Diana; Zheng Zhili; Hong Julie A; Downey Stephanie; Schrump David S; Rosenberg Steven A; Morgan Richard A
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
Cancer immunology, immunotherapy : CII 2009;58(3):383-94.
2009: Parkhurst Maria R; Joo Jayne; Riley John P; Yu Zhiya; Li Yong; Robbins Paul F; Rosenberg Steven A
Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):169-80.
2008: Solomon David A; Kim Jung-Sik; Cronin Julia C; Sibenaller Zita; Ryken Timothy; Rosenberg Steven A; Ressom Habtom; Jean Walter; Bigner Darell; Yan Hai; Samuels Yardena; Waldman Todd
Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
Cancer research 2008;68(24):10300-6.
2008: Ahmadzadeh Mojgan; Felipe-Silva Aloisio; Heemskerk Bianca; Powell Daniel J; Wunderlich John R; Merino Maria J; Rosenberg Steven A
FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.
Blood 2008;112(13):4953-60.
2008: Boni Andrea; Muranski Pawel; Cassard Lydie; Wrzesinski Claudia; Paulos Chrystal M; Palmer Douglas C; Gattinoni Luca; Hinrichs Christian S; Chan Chi-Chao; Rosenberg Steven A; Restifo Nicholas P
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
Blood 2008;112(12):4746-54.
2008: Yang Shicheng; Rosenberg Steven A; Morgan Richard A
Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(9):830-9.
2008: Dudley Mark E; Yang James C; Sherry Richard; Hughes Marybeth S; Royal Richard; Kammula Udai; Robbins Paul F; Huang JianPing; Citrin Deborah E; Leitman Susan F; Wunderlich John; Restifo Nicholas P; Thomasian Armen; Downey Stephanie G; Smith Franz O; Klapper Jacob; Morton Kathleen; Laurencot Carolyn; White Donald E; Rosenberg Steven A
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(32):5233-9.
2008: Yang S; Cohen C J; Peng P D; Zhao Y; Cassard L; Yu Z; Zheng Z; Jones S; Restifo N P; Rosenberg S A; Morgan R A
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.
Gene therapy 2008;15(21):1411-23.
2008: Tran Khoi Q; Zhou Juhua; Durflinger Katherine H; Langhan Michelle M; Shelton Thomas E; Wunderlich John R; Robbins Paul F; Rosenberg Steven A; Dudley Mark E
Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(8):742-51.
2008: Rosenberg Steven A; Dudley Mark E; Restifo Nicholas P
Cancer immunotherapy.
The New England journal of medicine 2008;359(10):1072.
2008: Smith Franz O; Downey Stephanie G; Klapper Jacob A; Yang James C; Sherry Richard M; Royal Richard E; Kammula Udai S; Hughes Marybeth S; Restifo Nicholas P; Levy Catherine L; White Donald E; Steinberg Seth M; Rosenberg Steven A
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5610-8.
2008: Rosenberg Steven A
Overcoming obstacles to the effective immunotherapy of human cancer.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(35):12643-4.
2008: Breunis Willemijn B; Tarazona-Santos Eduardo; Chen Renee; Kiley Maureen; Rosenberg Steven A; Chanock Stephen J
Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(6):586-90.
2008: Klapper Jacob A; Downey Stephanie G; Smith Franz O; Yang James C; Hughes Marybeth S; Kammula Udai S; Sherry Richard M; Royal Richard E; Steinberg Seth M; Rosenberg Steven
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.
Cancer 2008;113(2):293-301.
2008: Palmer Douglas C; Chan Chi-Chao; Gattinoni Luca; Wrzesinski Claudia; Paulos Chrystal M; Hinrichs Christian S; Powell Daniel J; Klebanoff Christopher A; Finkelstein Steven E; Fariss Robert N; Yu Zhiya; Nussenblatt Robert B; Rosenberg Steven A; Restifo Nicholas P
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(23):8061-6.
2008: Hinrichs Christian S; Spolski Rosanne; Paulos Chrystal M; Gattinoni Luca; Kerstann Keith W; Palmer Douglas C; Klebanoff Christopher A; Rosenberg Steven A; Leonard Warren J; Restifo Nicholas P
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.
Blood 2008;111(11):5326-33.
2008: Heemskerk Bianca; Liu Ke; Dudley Mark E; Johnson Laura A; Kaiser Andrew; Downey Stephanie; Zheng Zhili; Shelton Thomas E; Matsuda Kant; Robbins Paul F; Morgan Richard A; Rosenberg Steven A
Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.
Human gene therapy 2008;19(5):496-510.
2008: Robbins Paul F; Li Yong F; El-Gamil Mona; Zhao Yangbing; Wargo Jennifer A; Zheng Zhili; Xu Hui; Morgan Richard A; Feldman Steven A; Johnson Laura A; Bennett Alan D; Dunn Steven M; Mahon Tara M; Jakobsen Bent K; Rosenberg Steven A
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(9):6116-31.
2008: Rosenberg Steven A; Restifo Nicholas P; Yang James C; Morgan Richard A; Dudley Mark E
Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
Nature reviews. Cancer 2008;8(4):299-308.
2008: Powell Daniel J; Attia Peter; Ghetie Victor; Schindler John; Vitetta Ellen S; Rosenberg Steven A
Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(2):189-98.
2008: Abad John D; Wrzensinski Claudia; Overwijk Willem; De Witte Moniek A; Jorritsma Annelies; Hsu Cary; Gattinoni Luca; Cohen Cyrille J; Paulos Chrystal M; Palmer Douglas C; Haanen John B A G; Schumacher Ton N M; Rosenberg Steven A; Restifo Nicholas P; Morgan Richard A
T-cell receptor gene therapy of established tumors in a murine melanoma model.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(1):1-6.
2008: Rosenberg Steven A
Why perform sentinel-lymph-node biopsy in patients with melanoma?
Nature clinical practice. Oncology 2008;5(1):1.
2007: Dudley Mark E; Rosenberg Steven A
Adoptive cell transfer therapy.
Seminars in oncology 2007;34(6):524-31.
2007: Yang James C; Hughes Marybeth; Kammula Udai; Royal Richard; Sherry Richard M; Topalian Suzanne L; Suri Kimberly B; Levy Catherine; Allen Tamika; Mavroukakis Sharon; Lowy Israel; White Donald E; Rosenberg Steven A
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(8):825-30.
2007: Downey Stephanie G; Klapper Jacob A; Smith Franz O; Yang James C; Sherry Richard M; Royal Richard E; Kammula Udai S; Hughes Marybeth S; Allen Tamika E; Levy Catherine L; Yellin Michael; Nichol Geoffrey; White Donald E; Steinberg Seth M; Rosenberg Steven A
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(22 Pt 1):6681-8.
2007: Zhao Yangbing; Bennett Alan D; Zheng Zhili; Wang Qiong J; Robbins Paul F; Yu Lawrence Y L; Li Yi; Molloy Peter E; Dunn Steven M; Jakobsen Bent K; Rosenberg Steven A; Morgan Richard A
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(9):5845-54.
2007: Powell Daniel J; Felipe-Silva Aloisio; Merino Maria J; Ahmadzadeh Mojgan; Allen Tamika; Levy Catherine; White Donald E; Mavroukakis Sharon; Kreitman Robert J; Rosenberg Steven A; Pastan Ira
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(7):4919-28.
2007: Paulos Chrystal M; Kaiser Andrew; Wrzesinski Claudia; Hinrichs Christian S; Cassard Lydie; Boni Andrea; Muranski Pawel; Sanchez-Perez Luis; Palmer Douglas C; Yu Zhiya; Antony Paul A; Gattinoni Luca; Rosenberg Steven A; Restifo Nicholas P
Toll-like receptors in tumor immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5280-9.
2007: Rosenberg Steven A
Interleukin 2 for patients with renal cancer.
Nature clinical practice. Oncology 2007;4(9):497.
2007: Paulos Chrystal M; Wrzesinski Claudia; Kaiser Andrew; Hinrichs Christian S; Chieppa Marcello; Cassard Lydie; Palmer Douglas C; Boni Andrea; Muranski Pawel; Yu Zhiya; Gattinoni Luca; Antony Paul A; Rosenberg Steven A; Restifo Nicholas P
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.
The Journal of clinical investigation 2007;117(8):2197-204.
2007: Hsu Cary; Jones Stephanie A; Cohen Cyrille J; Zheng Zhili; Kerstann Keith; Zhou Juhua; Robbins Paul F; Peng Peter D; Shen Xinglei; Gomes Theotonius J; Dunbar Cynthia E; Munroe David J; Stewart Claudia; Cornetta Kenneth; Wangsa Danny; Ried Thomas; Rosenberg Steven A; Morgan Richard A
Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene.
Blood 2007;109(12):5168-77.
2007: Powell Daniel J; de Vries Christiaan R; Allen Tamika; Ahmadzadeh Mojgan; Rosenberg Steven A
Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(4):438-47.
2007: Cohen Cyrille J; Li Yong F; El-Gamil Mona; Robbins Paul F; Rosenberg Steven A; Morgan Richard A
Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.
Cancer research 2007;67(8):3898-903.
2007: Ahmadzadeh Mojgan; Antony Paul A; Rosenberg Steven A
IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(3):294-302.
2007: Zhao Yangbing; Parkhurst Maria R; Zheng Zhili; Cohen Cyrille J; Riley John P; Gattinoni Luca; Restifo Nicholas P; Rosenberg Steven A; Morgan Richard A
Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling.
Cancer research 2007;67(6):2425-9.
2007: Wrzesinski Claudia; Paulos Chrystal M; Gattinoni Luca; Palmer Douglas C; Kaiser Andrew; Yu Zhiya; Rosenberg Steven A; Restifo Nicholas P
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
The Journal of clinical investigation 2007;117(2):492-501.
2007: Smith Franz O; Goff Stephanie L; Klapper Jacob A; Levy Catherine; Allen Tamika; Mavroukakis Sharon A; Rosenberg Steven A
Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(1):130.
2007: Shen Xinglei; Zhou Juhua; Hathcock Karen S; Robbins Paul; Powell Daniel J; Rosenberg Steven A; Hodes Richard J
Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(1):123-9.
2006: Muranski Pawel; Boni Andrea; Wrzesinski Claudia; Citrin Deborah E; Rosenberg Steven A; Childs Richard; Restifo Nicholas P
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?
Nature clinical practice. Oncology 2006;3(12):668-81.
2006: Gattinoni Luca; Ranganathan Anju; Surman Deborah R; Palmer Douglas C; Antony Paul A; Theoret Marc R; Heimann David M; Rosenberg Steven A; Restifo Nicholas P
CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.
Blood 2006;108(12):3818-23.
2006: Lotem Michal; Zhao Yangbing; Riley John; Hwu Patrick; Morgan Richard A; Rosenberg Steven A; Parkhurst Maria R
Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(6):616-27.
2006: Johnson Laura A; Heemskerk Bianca; Powell Daniel J; Cohen Cyrille J; Morgan Richard A; Dudley Mark E; Robbins Paul F; Rosenberg Steven A
Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(9):6548-59.
2006: Powell Daniel J; Dudley Mark E; Hogan Katherine A; Wunderlich John R; Rosenberg Steven A
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(9):6527-39.
2006: Kershaw Michael H; Westwood Jennifer A; Parker Linda L; Wang Gang; Eshhar Zelig; Mavroukakis Sharon A; White Donald E; Wunderlich John R; Canevari Silvana; Rogers-Freezer Linda; Chen Clara C; Yang James C; Rosenberg Steven A; Hwu Patrick
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6106-15.
2006: Grover Amelia; Kim Grace J; Lizée Gregory; Tschoi Mary; Wang Gang; Wunderlich John R; Rosenberg Steven A; Hwang Sam T; Hwu Patrick
Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5801-8.
2006: Morgan Richard A; Dudley Mark E; Wunderlich John R; Hughes Marybeth S; Yang James C; Sherry Richard M; Royal Richard E; Topalian Suzanne L; Kammula Udai S; Restifo Nicholas P; Zheng Zhili; Nahvi Azam; de Vries Christiaan R; Rogers-Freezer Linda J; Mavroukakis Sharon A; Rosenberg Steven A
Cancer regression in patients after transfer of genetically engineered lymphocytes.
Science (New York, N.Y.) 2006;314(5796):126-9.
2006: Cohen Cyrille J; Zhao Yangbing; Zheng Zhili; Rosenberg Steven A; Morgan Richard A
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.
Cancer research 2006;66(17):8878-86.
2006: Maker Ajay V; Yang James C; Sherry Richard M; Topalian Suzanne L; Kammula Udai S; Royal Richard E; Hughes Marybeth; Yellin Michael J; Haworth Leah R; Levy Catherine; Allen Tamika; Mavroukakis Sharon A; Attia Peter; Rosenberg Steven A
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(4):455-63.
2006: Zhao Yangbing; Zheng Zhili; Khong Hung T; Rosenberg Steven A; Morgan Richard A
Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(4):398-406.
2006: Huang Jianping; Kerstann Keith W; Ahmadzadeh Mojgan; Li Yong F; El-Gamil Mona; Rosenberg Steven A; Robbins Paul F
Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(12):7726-35.
2006: Beck Kimberly E; Blansfield Joseph A; Tran Khoi Q; Feldman Andrew L; Hughes Marybeth S; Royal Richard E; Kammula Udai S; Topalian Suzanne L; Sherry Richard M; Kleiner David; Quezado Martha; Lowy Israel; Yellin Michael; Rosenberg Steven A; Yang James C
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2283-9.
2006: Shafer-Weaver Kimberly; Rosenberg Steven; Strobl Susan; Gregory Alvord W; Baseler Michael; Malyguine Anatoli
Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(3):328-35.
2006: Rosenberg Steven A; Sportès Claude; Ahmadzadeh Mojgan; Fry Terry J; Ngo Lien T; Schwarz Susan L; Stetler-Stevenson Maryalice; Morton Kathleen E; Mavroukakis Sharon A; Morre Michel; Buffet Renaud; Mackall Crystal L; Gress Ronald E
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(3):313-9.
2006: Liu Shujuan; Riley John; Rosenberg Steven; Parkhurst Maria
Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(3):284-93.
2006: Gattinoni Luca; Powell Daniel J; Rosenberg Steven A; Restifo Nicholas P
Adoptive immunotherapy for cancer: building on success.
Nature reviews. Immunology 2006;6(5):383-93.
2006: Lindsey Kimberly R; Gritz Linda; Sherry Richard; Abati Andrea; Fetsch Patricia A; Goldfeder Lisa C; Gonzales Monica I; Zinnack Kimberly A; Rogers-Freezer Linda; Haworth Leah; Mavroukakis Sharon A; White Donald E; Steinberg Seth M; Restifo Nicholas P; Panicali Dennis L; Rosenberg Steven A; Topalian Suzanne L
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(8):2526-37.
2006: Romeo Martin J; Wunderlich John; Ngo Lien; Rosenberg Steven A; Steinberg Seth M; Berman David M
Measuring tissue-based biomarkers by immunochromatography coupled with reverse-phase lysate microarray.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(8):2463-7.
2006: Rosenberg Steven A; Sherry Richard M; Morton Kathleen E; Yang James C; Topalian Suzanne L; Royal Richard E; Kammula Udai S; Restifo Nicholas P; Hughes Marybeth S; Schwarz Susan L; Ngo Lien T; Mavroukakis Sharon A; White Donald E
Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(2):224-31.
2006: Attia Peter; Powell Daniel J; Maker Ajay V; Kreitman Robert J; Pastan Ira; Rosenberg Steven A
Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(2):208-14.
2006: Ahmadzadeh Mojgan; Rosenberg Steven A
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
Blood 2006;107(6):2409-14.
2006: Jaber Samer H; Cowen Edward W; Haworth Leah R; Booher Susan L; Berman David M; Rosenberg Steven A; Hwang Sam T
Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent.
Archives of dermatology 2006;142(2):166-72.
2006: Zhao Yangbing; Zheng Zhili; Cohen Cyrille J; Gattinoni Luca; Palmer Douglas C; Restifo Nicholas P; Rosenberg Steven A; Morgan Richard A
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;13(1):151-9.
2005: Maker Ajay V; Attia Peter; Rosenberg Steven A
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(11):7746-54.
2005: Hsu Cary; Hughes Marybeth S; Zheng Zhili; Bray Regina B; Rosenberg Steven A; Morgan Richard A
Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(11):7226-34.
2005: Maker Ajay V; Phan Giao Q; Attia Peter; Yang James C; Sherry Richard M; Topalian Suzanne L; Kammula Udai S; Royal Richard E; Haworth Leah R; Levy Catherine; Kleiner David; Mavroukakis Sharon A; Yellin Michael; Rosenberg Steven A
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Annals of surgical oncology 2005;12(12):1005-16.
2005: Zhou Juhua; Shen Xinglei; Huang Jianping; Hodes Richard J; Rosenberg Steven A; Robbins Paul F
Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(10):7046-52.
2005: Rosenberg Steven A; Sherry Richard M; Morton Kathleen E; Scharfman William J; Yang James C; Topalian Suzanne L; Royal Richard E; Kammula Udai; Restifo Nicholas P; Hughes Marybeth S; Schwartzentruber Douglas; Berman David M; Schwarz Susan L; Ngo Lien T; Mavroukakis Sharon A; White Donald E; Steinberg Seth M
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(9):6169-76.
2005: Cohen Cyrille J; Zheng Zhili; Bray Regina; Zhao Yangbing; Sherman Linda A; Rosenberg Steven A; Morgan Richard A
Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(9):5799-808.
2005: Blansfield Joseph A; Beck Kimberly E; Tran Khoi; Yang James C; Hughes Marybeth S; Kammula Udai S; Royal Richard E; Topalian Suzanne L; Haworth Leah R; Levy Catherine; Rosenberg Steven A; Sherry Richard M
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(6):593-8.
2005: Attia Peter; Maker Ajay V; Haworth Leah R; Rogers-Freezer Linda; Rosenberg Steven A
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(6):582-92.
2005: Hinrichs Christian S; Palmer Douglas C; Rosenberg Steven A; Restifo Nicholas P
Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(6):517-24.
2005: Gattinoni Luca; Finkelstein Steven E; Klebanoff Christopher A; Antony Paul A; Palmer Douglas C; Spiess Paul J; Hwang Leroy N; Yu Zhiya; Wrzesinski Claudia; Heimann David M; Surh Charles D; Rosenberg Steven A; Restifo Nicholas P
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
The Journal of experimental medicine 2005;202(7):907-12.
2005: Aisner Dara L; Maker Ajay; Rosenberg Steven A; Berman David M
Loss of S100 antigenicity in metastatic melanoma.
Human pathology 2005;36(9):1016-9.
2005: Attia Peter; Phan Giao Q; Maker Ajay V; Robinson Michael R; Quezado Martha M; Yang James C; Sherry Richard M; Topalian Suzanne L; Kammula Udai S; Royal Richard E; Restifo Nicholas P; Haworth Leah R; Levy Catherine; Mavroukakis Sharon A; Nichol Geoff; Yellin Michael J; Rosenberg Steven A
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):6043-53.
2005: Powell Daniel J; Parker Linda L; Rosenberg Steven A
Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(4):403-11.
2005: Klebanoff Christopher A; Gattinoni Luca; Torabi-Parizi Parizad; Kerstann Keith; Cardones Adela R; Finkelstein Steven E; Palmer Douglas C; Antony Paul A; Hwang Sam T; Rosenberg Steven A; Waldmann Thomas A; Restifo Nicholas P
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(27):9571-6.
2005: Gattinoni Luca; Klebanoff Christopher A; Palmer Douglas C; Wrzesinski Claudia; Kerstann Keith; Yu Zhiya; Finkelstein Steven E; Theoret Marc R; Rosenberg Steven A; Restifo Nicholas P
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
The Journal of clinical investigation 2005;115(6):1616-26.
2005: Rosenberg Steven A
The emergence of modern cancer immunotherapy.
Annals of surgical oncology 2005;12(5):344-6.
2005: Ahmadzadeh Mojgan; Rosenberg Steven A
TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(9):5215-23.
2005: Huang Jianping; Khong Hung T; Dudley Mark E; El-Gamil Mona; Li Yong F; Rosenberg Steven A; Robbins Paul F
Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(3):258-67.
2005: Hughes Marybeth S; Yu Yik Y L; Dudley Mark E; Zheng Zhili; Robbins Paul F; Li Yong; Wunderlich John; Hawley Robert G; Moayeri Morvarid; Rosenberg Steven A; Morgan Richard A
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.
Human gene therapy 2005;16(4):457-72.
2005: Dudley Mark E; Wunderlich John R; Yang James C; Sherry Richard M; Topalian Suzanne L; Restifo Nicholas P; Royal Richard E; Kammula Udai; White Don E; Mavroukakis Sharon A; Rogers Linda J; Gracia Gerald J; Jones Stephanie A; Mangiameli David P; Pelletier Michelle M; Gea-Banacloche Juan; Robinson Michael R; Berman David M; Filie Armando C; Abati Andrea; Rosenberg Steven A
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2346-57.
2005: Zhao Yangbing; Zheng Zhili; Robbins Paul F; Khong Hung T; Rosenberg Steven A; Morgan Richard A
Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(7):4415-23.
2005: Rosenberg Steven A
Cancer immunotherapy comes of age.
Nature clinical practice. Oncology 2005;2(3):115.
2005: Charo Jehad; Finkelstein Steven E; Grewal Navrose; Restifo Nicholas P; Robbins Paul F; Rosenberg Steven A
Bcl-2 overexpression enhances tumor-specific T-cell survival.
Cancer research 2005;65(5):2001-8.
2005: Antony Paul A; Piccirillo Ciriaco A; Akpinarli Akgül; Finkelstein Steven E; Speiss Paul J; Surman Deborah R; Palmer Douglas C; Chan Chi-Chao; Klebanoff Christopher A; Overwijk Willem W; Rosenberg Steven A; Restifo Nicholas P
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(5):2591-601.
2005: Rosenberg Steven A
Cell transfer and other immunotherapeutic strategies.
Clinical advances in hematology & oncology : H&O 2005;3(1):28-9.
2005: Restifo Nicholas P; Rosenberg Steven A
Use of standard criteria for assessment of cancer vaccines.
The lancet oncology 2005;6(1):3-4.
2005: Zhou Juhua; Dudley Mark E; Rosenberg Steven A; Robbins Paul F
Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(1):53-62.
2005: Powell Daniel J; Dudley Mark E; Robbins Paul F; Rosenberg Steven A
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.
Blood 2005;105(1):241-50.
2004: Zhou Juhua; Dudley Mark E; Rosenberg Steven A; Robbins Paul F
Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(12):7622-9.
2004: Robbins Paul F; Dudley Mark E; Wunderlich John; El-Gamil Mona; Li Yong F; Zhou Juhua; Huang Jianping; Powell Daniel J; Rosenberg Steven A
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(12):7125-30.
2004: Robinson Michael R; Chan Chi-Chao; Yang James C; Rubin Benjamin I; Gracia Gerald J; Sen H Nida; Csaky Karl G; Rosenberg Steven A
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(6):478-9.
2004: Khong Hung T; Yang James C; Topalian Suzanne L; Sherry Richard M; Mavroukakis Sharon A; White Donald E; Rosenberg Steven A
Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(6):472-7.
2004: Rosenberg Steven A; Dudley Mark E
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.
Proceedings of the National Academy of Sciences of the United States of America 2004;101 Suppl 2():14639-45.
2004: Rosenberg Steven A; Yang James C; Restifo Nicholas P
Cancer immunotherapy: moving beyond current vaccines.
Nature medicine 2004;10(9):909-15.
2004: Finkelstein Steven E; Carrasquillo Jorge A; Hoffman John M; Galen Barbara; Choyke Peter; White Donald E; Rosenberg Steven A; Sherry Richard M
A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy.
Annals of surgical oncology 2004;11(8):731-8.
2004: Finkelstein Steven E; Heimann David M; Klebanoff Christopher A; Antony Paul A; Gattinoni Luca; Hinrichs Christian S; Hwang Leroy N; Palmer Douglas C; Spiess Paul J; Surman Deborah R; Wrzesiniski Claudia; Yu Zhiya; Rosenberg Steven A; Restifo Nicholas P
Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer.
Journal of leukocyte biology 2004;76(2):333-7.
2004: Parkhurst Maria R; Riley John P; Igarashi Takehito; Li Yong; Robbins Paul F; Rosenberg Steven A
Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4688-98.
2004: Elaraj Dina M; White Donald E; Steinberg Seth M; Haworth Leah; Rosenberg Steven A; Yang James C
A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(4):259-64.
2004: Huang Jianping; El-Gamil Mona; Dudley Mark E; Li Yong F; Rosenberg Steven A; Robbins Paul F
T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(10):6057-64.
2004: Rosenberg Steven A
Development of effective immunotherapy for the treatment of patients with cancer.
Journal of the American College of Surgeons 2004;198(5):685-96.
2004: Khong Hung T; Wang Qiong J; Rosenberg Steven A
Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(3):184-90.
2004: Rosenberg Steven A
Shedding light on immunotherapy for cancer.
The New England journal of medicine 2004;350(14):1461-3.
2004: Parkhurst Maria R; Riley John P; Robbins Paul F; Rosenberg Steven A
Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(2):79-91.
2004: Klebanoff Christopher A; Finkelstein Steven E; Surman Deborah R; Lichtman Michael K; Gattinoni Luca; Theoret Marc R; Grewal Navrose; Spiess Paul J; Antony Paul A; Palmer Douglas C; Tagaya Yutaka; Rosenberg Steven A; Waldmann Thomas A; Restifo Nicholas P
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(7):1969-74.
2004: Powell Daniel J; Rosenberg Steven A
Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(1):36-47.
2003: Maccalli Cristina; Li Yong F; El-Gamil Mona; Rosenberg Steven A; Robbins Paul F
Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.
Cancer research 2003;63(20):6735-43.
2003: Rosenberg Steven A; Yang James C; Robbins Paul F; Wunderlich John R; Hwu Patrick; Sherry Richard M; Schwartzentruber Douglas J; Topalian Suzanne L; Restifo Nicholas P; Filie Armando; Chang Richard; Dudley Mark E
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(5):385-93.
2003: Morgan Richard A; Dudley Mark E; Yu Yik Y L; Zheng Zhili; Robbins Paul F; Theoret Marc R; Wunderlich John R; Hughes Marybeth S; Restifo Nicholas P; Rosenberg Steven A
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(6):3287-95.
2003: Dudley Mark E; Rosenberg Steven A
Adoptive-cell-transfer therapy for the treatment of patients with cancer.
Nature reviews. Cancer 2003;3(9):666-75.
2003: Nagorsen D; Panelli M; Dudley M E; Finkelstein S E; Rosenberg S A; Marincola F M
Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.
Gene therapy 2003;10(20):1754-65.
2003: Overwijk Willem W; Theoret Marc R; Finkelstein Steven E; Surman Deborah R; de Jong Laurina A; Vyth-Dreese Florry A; Dellemijn Trees A; Antony Paul A; Spiess Paul J; Palmer Douglas C; Heimann David M; Klebanoff Christopher A; Yu Zhiya; Hwang Leroy N; Feigenbaum Lionel; Kruisbeek Ada M; Rosenberg Steven A; Restifo Nicholas P
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
The Journal of experimental medicine 2003;198(4):569-80.
2003: Yang James C; Sherry Richard M; Steinberg Seth M; Topalian Suzanne L; Schwartzentruber Douglas J; Hwu Patrick; Seipp Claudia A; Rogers-Freezer Linda; Morton Kathleen E; White Donald E; Liewehr David J; Merino Maria J; Rosenberg Steven A
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(16):3127-32.
2003: Rosenberg Steven A; Yang James C; Schwartzentruber Douglas J; Hwu Patrick; Topalian Suzanne L; Sherry Richard M; Restifo Nicholas P; Wunderlich John R; Seipp Claudia A; Rogers-Freezer Linda; Morton Kathleen E; Mavroukakis Sharon A; Gritz Linda; Panicali Dennis L; White Donald E
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(8):2973-80.
2003: Yang James C; Haworth Leah; Sherry Richard M; Hwu Patrick; Schwartzentruber Douglas J; Topalian Suzanne L; Steinberg Seth M; Chen Helen X; Rosenberg Steven A
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
The New England journal of medicine 2003;349(5):427-34.
2003: Phan Giao Q; Touloukian Christopher E; Yang James C; Restifo Nicholas P; Sherry Richard M; Hwu Patrick; Topalian Suzanne L; Schwartzentruber Douglas J; Seipp Claudia A; Freezer Linda J; Morton Kathleen E; Mavroukakis Sharon A; White Donald E; Rosenberg Steven A
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(4):349-56.
2003: Dudley Mark E; Wunderlich John R; Shelton Thomas E; Even Jos; Rosenberg Steven A
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(4):332-42.
2003: Phan Giao Q; Yang James C; Sherry Richard M; Hwu Patrick; Topalian Suzanne L; Schwartzentruber Douglas J; Restifo Nicholas P; Haworth Leah R; Seipp Claudia A; Freezer Linda J; Morton Kathleen E; Mavroukakis Sharon A; Duray Paul H; Steinberg Seth M; Allison James P; Davis Thomas A; Rosenberg Steven A
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(14):8372-7.
2003: Barrett J Carl; Bennett L Michelle; Fleming Laura Kay; Linehan W Marston; Liotta Lance A; Rosenberg Steven A; Petricoin Emanuel F; Staudt Louis M; Thompson Tracy E; Yang James C
Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research.
Clinical advances in hematology & oncology : H&O 2003;1(5):302-6.
2003: Liu Ke; Rosenberg Steven A
Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(3):190-201.
2003: Rosenberg Steven A; Yang James C; Sherry Richard M; Hwu Patrick; Topalian Suzanne L; Schwartzentruber Douglas J; Restifo Nicholas P; Haworth Leah R; Seipp Claudia A; Freezer Linda J; Morton Kathleen E; Mavroukakis Sharon A; White Donald E
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
Human gene therapy 2003;14(8):709-14.
2003: Riley John P; Rosenberg Steven A; Parkhurst Maria R
Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
Journal of immunological methods 2003;276(1-2):103-19.
2003: Parkhurst Maria R; DePan Cormac; Riley John P; Rosenberg Steven A; Shu Suyu
Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(10):5317-25.
2003: Heimann David M; Rosenberg Steven A
Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(2):179-80.
2003: Attia Peter; Phan Giao Q; Duray Paul H; Rosenberg Steven A
Parathyroid hormone-related protein and hypercalcemia in patients with metastatic melanoma: case report and review.
American journal of clinical oncology 2003;26(1):42-5.
2003: Touloukian Christopher E; Leitner Wolfgang W; Schnur Rhonda E; Robbins Paul F; Li Yong; Southwood Scott; Sette Alessandro; Rosenberg Steven A; Restifo Nicholas P
Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(3):1579-85.
2003: Javia Luv Ram; Rosenberg Steven A
CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(1):85-93.
2002: Robbins Paul F; El-Gamil Mona; Li Yong F; Zeng Gang; Dudley Mark; Rosenberg Steven A
Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(10):6036-47.
2002: Dudley Mark E; Wunderlich John R; Robbins Paul F; Yang James C; Hwu Patrick; Schwartzentruber Douglas J; Topalian Suzanne L; Sherry Richard; Restifo Nicholas P; Hubicki Amy M; Robinson Michael R; Raffeld Mark; Duray Paul; Seipp Claudia A; Rogers-Freezer Linda; Morton Kathleen E; Mavroukakis Sharon A; White Donald E; Rosenberg Steven A
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Science (New York, N.Y.) 2002;298(5594):850-4.
2002: Touloukian Christopher E; Leitner Wolfgang W; Robbins Paul F; Li Yong F; Kang Xiaoqiang; Lapointe Rejean; Hwu Patrick; Rosenberg Steven A; Restifo Nicholas P
Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.
Cancer research 2002;62(18):5144-7.
2002: Zeng Gang; Li Yong; El-Gamil Mona; Sidney John; Sette Alexandro; Wang Rong-fu; Rosenberg Steven A; Robbins Paul F
Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.
Cancer research 2002;62(13):3630-5.
2002: Wang Ena; Miller Lance D; Ohnmacht Galen A; Mocellin Simone; Perez-Diez Ainhoa; Petersen David; Zhao Yingdong; Simon Richard; Powell John I; Asaki Esther; Alexander H Richard; Duray Paul H; Herlyn Meenhard; Restifo Nicholas P; Liu Edison T; Rosenberg Steven A; Marincola Francesco M
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness.
Cancer research 2002;62(13):3581-6.
2002: Khong Hung T; Rosenberg Steven A
The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy.
Cancer research 2002;62(11):3020-3.
2002: Monsurrò Vladia; Nagorsen Dirk; Wang Ena; Provenzano Maurizio; Dudley Mark E; Rosenberg Steven A; Marincola Francesco M
Functional heterogeneity of vaccine-induced CD8(+) T cells.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(11):5933-42.
2002: Marroquin Carlos E; Westwood Jennifer A; Lapointe Rejean; Mixon Arnold; Wunderlich John R; Caron Dania; Rosenberg Steven A; Hwu Patrick
Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(3):278-88.
2002: Seiter Simone; Monsurro Vladia; Nielsen Mai-Britt; Wang Ena; Provenzano Maurizio; Wunderlich John R; Rosenberg Steven A; Marincola Francesco M
Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(3):252-63.
2002: Dudley Mark E; Wunderlich John R; Yang James C; Hwu Patrick; Schwartzentruber Douglas J; Topalian Suzanne L; Sherry Richard M; Marincola Francesco M; Leitman Susan F; Seipp Claudia A; Rogers-Freezer Linda; Morton Kathleen E; Nahvi Azam; Mavroukakis Sharon A; White Donald E; Rosenberg Steven A
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(3):243-51.
2002: Rosenberg Steven A; Spiess Paul J; Kleiner David E
Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(3):218-25.
2002: Weinreich David M; Rosenberg Steven A
Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(2):185-7.
2002: Rosenberg Steven A; Tong-On Panida; Li Yong; Riley John P; El-Gamil Mona; Parkhurst Maria R; Robbins Paul F
Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(5):2402-7.
2002: Guirguis Lisa M; Yang James C; White Donald E; Steinberg Seth M; Liewehr David J; Rosenberg Steven A; Schwartzentruber Douglas J
Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(1):82-7.
2002: Thurber Stacy E; Khong Hung T; Kammula Udai S; Rosenberg Steven A
Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(1):63-71.
2002: McKee Mark D; Cecco Stacey A; Niemela Julie E; Cormier Janice; Kim Christina J; Steinberg Seth M; Rehak Nadja N; Elin Ronald J; Rosenberg Steven A
Effects of interleukin 2 therapy on lymphocyte magnesium levels.
The Journal of laboratory and clinical medicine 2002;139(1):5-12.
2002: Khong Hung T; Rosenberg Steven A
Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(2):951-6.
2002: Toso John F; Gill Vee J; Hwu Patrick; Marincola Francesco M; Restifo Nicholas P; Schwartzentruber Douglas J; Sherry Richard M; Topalian Suzanne L; Yang James C; Stock Frida; Freezer Linda J; Morton Kathleen E; Seipp Claudia; Haworth Leah; Mavroukakis Sharon; White Donald; MacDonald Susan; Mao John; Sznol Mario; Rosenberg Steven A
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):142-52.
2001: Rosenberg S A
Progress in the development of immunotherapy for the treatment of patients with cancer.
Journal of internal medicine 2001;250(6):462-75.
2001: Liu K; Rosenberg S A
Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(11):6356-65.
2001: Rosenberg S A
Cellular therapy: an introduction.
Cancer journal (Sudbury, Mass.) 2001;7 Suppl 2():S51-2.
2001: Mocellin S; Fetsch P; Abati A; Phan G Q; Wang E; Provenzano M; Stroncek D; Rosenberg S A; Marincola F M
Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(6):447-58.
2001: Touloukian C E; Leitner W W; Robbins P F; Rosenberg S A; Restifo N P
Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.
Cancer research 2001;61(22):8100-4.
2001: Phan G Q; Attia P; Steinberg S M; White D E; Rosenberg S A
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(15):3477-82.
2001: Ohnmacht G A; Wang E; Mocellin S; Abati A; Filie A; Fetsch P; Riker A I; Kammula U S; Rosenberg S A; Marincola F M
Short-term kinetics of tumor antigen expression in response to vaccination.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(3):1809-20.
2001: Dudley M E; Wunderlich J; Nishimura M I; Yu D; Yang J C; Topalian S L; Schwartzentruber D J; Hwu P; Marincola F M; Sherry R; Leitman S F; Rosenberg S A
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(4):363-73.
2001: Harada M; Li Y F; El-Gamil M; Ohnmacht G A; Rosenberg S A; Robbins P F
Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(4):323-33.
2001: Vasselli J R; Yang J C; Linehan W M; White D E; Rosenberg S A; Walther M M
Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
The Journal of urology 2001;166(1):68-72.
2001: Riley J P; Rosenberg S A; Parkhurst M R
Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(3):212-20.
2001: Rosenberg S A
Progress in human tumour immunology and immunotherapy.
Nature 2001;411(6835):380-4.
2001: Monsurrò V; Nielsen M B; Perez-Diez A; Dudley M E; Wang E; Rosenberg S A; Marincola F M
Kinetics of TCR use in response to repeated epitope-specific immunization.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(9):5817-25.
2001: Ohnmacht G A; Phan G Q; Mavroukakis S A; Steinberg S M; Shea Y R; Witebsky F G; McIntyre L S; Goodwin R S; Muehlbauer P M; Morton K E; Rogers-Freezer L J; Seipp C A; Rosenberg S A; Marincola F M
A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(2):188-92.
2001: Weiser T S; Guo Z S; Ohnmacht G A; Parkhurst M L; Tong-On P; Marincola F M; Fischette M R; Yu X; Chen G A; Hong J A; Stewart J H; Nguyen D M; Rosenberg S A; Schrump D S
Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(2):151-61.
2001: Zeng G; Wang X; Robbins P F; Rosenberg S A; Wang R F
CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(7):3964-9.
2001: Harada M; Li Y F; El-Gamil M; Rosenberg S A; Robbins P F
Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.
Cancer research 2001;61(3):1089-94.
2001: Chang E; Rosenberg S A
Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(1):88-90.
2001: Bownds S; Tong-On P; Rosenberg S A; Parkhurst M
Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(1):1-9.
2001: Horning S J; Negrin R S; Hoppe R T; Rosenberg S A; Chao N J; Long G D; Brown B W; Blume K G
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial.
Blood 2001;97(2):404-9.
2000: Parker L L; Do M T; Westwood J A; Wunderlich J R; Dudley M E; Rosenberg S A; Hwu P
Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer.
Human gene therapy 2000;11(17):2377-87.
2000: Fritsch M; Rosenberg S A; Duray P H
Immunohistologic responses within dermal metastatic melanoma lesions of patients treated with a synthetic peptide vaccine.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(5):557-69.
2000: Kammula U S; Marincola F M; Rosenberg S A
Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination.
Journal of the National Cancer Institute 2000;92(16):1336-44.
2000: Nielsen M B; Monsurro V; Migueles S A; Wang E; Perez-Diez A; Lee K H; Kammula U; Rosenberg S A; Marincola F M
Status of activation of circulating vaccine-elicited CD8+ T cells.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(4):2287-96.
2000: Panelli M C; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg S A; Marincola F M
Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(4):487-98.
2000: McKee M D; Clay T M; Diamond R A; Rosenberg S A; Nishimura M I
Quantitation of T-cell receptor frequencies by competitive polymerase chain reaction: dynamics of T-cell clonotype frequencies in an expanding tumor-infiltrating lymphocyte culture.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(4):419-29.
2000: Stewart J H; Rosenberg S A
Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(4):401-4.
2000: Zeng G; Touloukian C E; Wang X; Restifo N P; Rosenberg S A; Wang R F
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(2):1153-9.
2000: Riker A I; Kammula U S; Panelli M C; Wang E; Ohnmacht G A; Steinberg S M; Rosenberg S A; Marincola F M
Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes.
International journal of cancer. Journal international du cancer 2000;86(6):818-26.
2000: Rosenberg S A
Identification of cancer antigens: impact on development of cancer immunotherapies.
Cancer journal (Sudbury, Mass.) 2000;6 Suppl 3():S200-7.
2000: Marroquin C E; White D E; Steinberg S M; Rosenberg S A; Schwartzentruber D J
Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(3):387-92.
2000: Lindsey K R; Rosenberg S A; Sherry R M
Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(9):1954-9.
2000: Rosenberg S A
The identification of cancer antigens: impact on the development of cancer vaccines.
Cancer journal (Sudbury, Mass.) 2000;6 Suppl 2():S142-9.
2000: Panelli M C; Bettinotti M P; Lally K; Ohnmacht G A; Li Y; Robbins P; Riker A; Rosenberg S A; Marincola F M
A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(8):4382-92.
2000: Touloukian C E; Leitner W W; Topalian S L; Li Y F; Robbins P F; Rosenberg S A; Restifo N P
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(7):3535-42.
2000: Dudley M E; Ngo L T; Westwood J; Wunderlich J R; Rosenberg S A
T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Cancer journal (Sudbury, Mass.) 2000;6(2):69-77.
2000: Atkins M B; Kunkel L; Sznol M; Rosenberg S A
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
The cancer journal from Scientific American 2000;6 Suppl 1():S11-4.
2000: Rosenberg S A
Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.
The cancer journal from Scientific American 2000;6 Suppl 1():S2-7.
2000: Ladányi A; Nishimura M I; Rosenberg S A; Yang J C
Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(1):36-47.
2000: Kawakami Y; Dang N; Wang X; Tupesis J; Robbins P F; Wang R F; Wunderlich J R; Yannelli J R; Rosenberg S A
Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(1):17-27.
2000: Panelli M C; Riker A; Kammula U; Wang E; Lee K H; Rosenberg S A; Marincola F M
Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(1):495-504.
1999: Nishimura M I; Avichezer D; Custer M C; Lee C S; Chen C; Parkhurst M R; Diamond R A; Robbins P F; Schwartzentruber D J; Rosenberg S A
MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.
Cancer research 1999;59(24):6230-8.
1999: Kammula U S; Lee K H; Riker A I; Wang E; Ohnmacht G A; Rosenberg S A; Marincola F M
Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(12):6867-75.
1999: Lee K H; Wang E; Nielsen M B; Wunderlich J; Migueles S; Connors M; Steinberg S M; Rosenberg S A; Marincola F M
Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(11):6292-300.
1999: Kaufman H L; Rao J B; Irvine K R; Bronte V; Rosenberg S A; Restifo N P;
Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(6):489-96.
1999: Touloukian C E; Rosenberg S A
A survey of treatments used in patients with metastatic melanoma: analysis of 189 patients referred to the National Cancer Institute.
The cancer journal from Scientific American 1999;5(5):269-74.
1999: Wang R F; Rosenberg S A
Human tumor antigens for cancer vaccine development.
Immunological reviews 1999;170():85-100.
1999: Riker A; Cormier J; Panelli M; Kammula U; Wang E; Abati A; Fetsch P; Lee K H; Steinberg S; Rosenberg S; Marincola F
Immune selection after antigen-specific immunotherapy of melanoma.
Surgery 1999;126(2):112-20.
1999: Rosenberg S A; Yang J C; Schwartzentruber D J; Hwu P; Marincola F M; Topalian S L; Restifo N P; Sznol M; Schwarz S L; Spiess P J; Wunderlich J R; Seipp C A; Einhorn J H; Rogers-Freezer L; White D E
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(3):1690-5.
1999: Atkins M B; Lotze M T; Dutcher J P; Fisher R I; Weiss G; Margolin K; Abrams J; Sznol M; Parkinson D; Hawkins M; Paradise C; Kunkel L; Rosenberg S A
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2105-16.
1999: Hurst R; White D E; Heiss J; Lee D S; Rosenberg S A; Schwartzentruber D J
Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated?
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(4):356-62.
1999: Dudley M E; Nishimura M I; Holt A K; Rosenberg S A
Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(4):288-98.
1999: Clay T M; Custer M C; Sachs J; Hwu P; Rosenberg S A; Nishimura M I
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(1):507-13.
1999: Wagner J R; Walther M M; Linehan W M; White D E; Rosenberg S A; Yang J C
Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place.
The Journal of urology 1999;162(1):43-5.
1999: Irvine K R; Parkhurst M R; Shulman E P; Tupesis J P; Custer M; Touloukian C E; Robbins P F; Yafal A G; Greenhalgh P; Sutmuller R P; Offringa R; Rosenberg S A; Restifo N P
Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.
Cancer research 1999;59(11):2536-40.
1999: Wang R F; Wang X; Atwood A C; Topalian S L; Rosenberg S A
Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen.
Science (New York, N.Y.) 1999;284(5418):1351-4.
1999: Wang R F; Wang X; Rosenberg S A
Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells.
The Journal of experimental medicine 1999;189(10):1659-68.
1999: Rosenberg S A
A new era of cancer immunotherapy: converting theory to performance.
CA: a cancer journal for clinicians 1999;49(2):70-3, 65.
1999: Rosenberg S A
A new era for cancer immunotherapy based on the genes that encode cancer antigens.
Immunity 1999;10(3):281-7.
1999: McKee M D; Clay T M; Rosenberg S A; Nishimura M I
Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(2):93-102.
1999: Zaks T Z; Chappell D B; Rosenberg S A; Restifo N P
Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(6):3273-9.
1999: Overwijk W W; Lee D S; Surman D R; Irvine K R; Touloukian C E; Chan C C; Carroll M W; Moss B; Rosenberg S A; Restifo N P
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(6):2982-7.
1999: Rosenberg S A; Yang J C; Schwartzentruber D J; Hwu P; Marincola F M; Topalian S L; Seipp C A; Einhorn J H; White D E; Steinberg S M
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):968-75.
1999: Pieper R; Christian R E; Gonzales M I; Nishimura M I; Gupta G; Settlage R E; Shabanowitz J; Rosenberg S A; Hunt D F; Topalian S L
Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells.
The Journal of experimental medicine 1999;189(5):757-66.
1999: Clay T M; Custer M C; McKee M D; Parkhurst M; Robbins P F; Kerstann K; Wunderlich J; Rosenberg S A; Nishimura M I
Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(3):1749-55.
1999: Lee L; Wang R F; Wang X; Mixon A; Johnson B E; Rosenberg S A; Schrump D S
NY-ESO-1 may be a potential target for lung cancer immunotherapy.
The cancer journal from Scientific American 1999;5(1):20-5.
1999: Zeh H J; Perry-Lalley D; Dudley M E; Rosenberg S A; Yang J C
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(2):989-94.
1999: Restifo N P; Rosenberg S A
Developing recombinant and synthetic vaccines for the treatment of melanoma.
Current opinion in oncology 1999;11(1):50-7.
1999: Chappell D B; Zaks T Z; Rosenberg S A; Restifo N P
Human melanoma cells do not express Fas (Apo-1/CD95) ligand.
Cancer research 1999;59(1):59-62.
1999: Riker A I; Panelli M C; Kammula U S; Wang E; Wunderlich J; Abati A; Fetsch P; Rosenberg S A; Marincola F M
Development and characterization of melanoma cell lines established by fine-needle aspiration biopsy: advances in the monitoring of patients with metastatic melanoma.
Cancer detection and prevention 1999;23(5):387-96.
1998: Kawakami Y; Robbins P F; Wang X; Tupesis J P; Parkhurst M R; Kang X; Sakaguchi K; Appella E; Rosenberg S A
Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(12):6985-92.
1998: Rosenberg S A; Zhai Y; Yang J C; Schwartzentruber D J; Hwu P; Marincola F M; Topalian S L; Restifo N P; Seipp C A; Einhorn J H; Roberts B; White D E
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
Journal of the National Cancer Institute 1998;90(24):1894-900.
1998: Bronte V; Wang M; Overwijk W W; Surman D R; Pericle F; Rosenberg S A; Restifo N P
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(10):5313-20.
1998: Zaks T Z; Rosenberg S A
Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
Cancer research 1998;58(21):4902-8.
1998: Parkhurst M R; Fitzgerald E B; Southwood S; Sette A; Rosenberg S A; Kawakami Y
Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2).
Cancer research 1998;58(21):4895-901.
1998: Lee K H; Panelli M C; Kim C J; Riker A I; Bettinotti M P; Roden M M; Fetsch P; Abati A; Rosenberg S A; Marincola F M
Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(8):4183-94.
1998: Wang R F; Johnston S L; Zeng G; Topalian S L; Schwartzentruber D J; Rosenberg S A
A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(7):3598-606.
1998: Pass H A; Schwarz S L; Wunderlich J R; Rosenberg S A
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
The cancer journal from Scientific American 1998;4(5):316-23.
1998: Nishimura M I; Custer M C; Schwarz S L; Parker L L; Mixon A; Clay T M; Yannelli J R; Rosenberg S A
T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(5):352-62.
1998: Rosenberg S A; Yang J C; White D E; Steinberg S M
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
Annals of surgery 1998;228(3):307-19.
1998: Restifo N P; Surman D R; Zheng H; Palese P; Rosenberg S A; García-Sastre A
Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer.
Virology 1998;249(1):89-97.
1998: Wang R F; Wang X; Johnston S L; Zeng G; Robbins P F; Rosenberg S A
Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens.
Cancer research 1998;58(16):3519-25.
1998: Kammula U S; White D E; Rosenberg S A
Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
Cancer 1998;83(4):797-805.
1998: Kawakami Y; Robbins P F; Wang R F; Parkhurst M; Kang X; Rosenberg S A
The use of melanosomal proteins in the immunotherapy of melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(4):237-46.
1998: Overwijk W W; Tsung A; Irvine K R; Parkhurst M R; Goletz T J; Tsung K; Carroll M W; Liu C; Moss B; Rosenberg S A; Restifo N P
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
The Journal of experimental medicine 1998;188(2):277-86.
1998: Surman D R; Irvine K R; Shulman E P; Allweis T M; Rosenberg S A; Restifo N P
Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.
Journal of immunological methods 1998;214(1-2):51-62.
1998: Rosenberg S A
New opportunities for the development of cancer immunotherapies.
The cancer journal from Scientific American 1998;4 Suppl 1():S1-4.
1998: Alexander H R; Bartlett D L; Libutti S K; Fraker D L; Moser T; Rosenberg S A
Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1479-89.
1998: Lee D S; White D E; Hurst R; Rosenberg S A; Yang J C
Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
The cancer journal from Scientific American 1998;4(2):86-93.
1998: Rosenberg S A; Yang J C; Schwartzentruber D J; Hwu P; Marincola F M; Topalian S L; Restifo N P; Dudley M E; Schwarz S L; Spiess P J; Wunderlich J R; Parkhurst M R; Kawakami Y; Seipp C A; Einhorn J H; White D E
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.
Nature medicine 1998;4(3):321-7.
1998: Walther M M; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang J C; Linehan W M; Rosenberg S A
Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
The Journal of urology 1998;159(3):718-22.
1998: Cormier J N; Hijazi Y M; Abati A; Fetsch P; Bettinotti M; Steinberg S M; Rosenberg S A; Marincola F M
Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
International journal of cancer. Journal international du cancer 1998;75(4):517-24.
1998: Wang G; Chopra R K; Royal R E; Yang J C; Rosenberg S A; Hwu P
A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen.
Nature medicine 1998;4(2):168-72.
1998: Wang R F; Johnston S L; Southwood S; Sette A; Rosenberg S A
Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(2):890-7.
1998: Kim C J; Cormier J; Roden M; Gritz L; Mazzara G P; Fetsch P; Hijazi Y; Lee K H; Rosenberg S A; Marincola F M
Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity.
Annals of surgical oncology 1998;5(1):64-76.
1998: Cormier J N; Abati A; Fetsch P; Hijazi Y M; Rosenberg S A; Marincola F M; Topalian S L
Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(1):27-31.
1998: Yang J C; Chang A E; Baker A R; Sindelar W F; Danforth D N; Topalian S L; DeLaney T; Glatstein E; Steinberg S M; Merino M J; Rosenberg S A
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):197-203.
1997: Yang J C; Rosenberg S A
An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
The cancer journal from Scientific American 1997;3 Suppl 1():S79-84.
1997: Rosenberg S A
Keynote address: perspectives on the use of interleukin-2 in cancer treatment.
The cancer journal from Scientific American 1997;3 Suppl 1():S2-6.
1997: Irvine K R; Chamberlain R S; Shulman E P; Surman D R; Rosenberg S A; Restifo N P
Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.
Journal of the National Cancer Institute 1997;89(21):1595-601.
1997: Walther M M; Yang J C; Pass H I; Linehan W M; Rosenberg S A
Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma.
The Journal of urology 1997;158(5):1675-8.
1997: Specht J M; Wang G; Do M T; Lam J S; Royal R E; Reeves M E; Rosenberg S A; Hwu P
Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases.
The Journal of experimental medicine 1997;186(8):1213-21.
1997: Cormier J N; Hurst R; Vasselli J; Lee D; Kim C J; McKee M; Venzon D; White D; Marincola F M; Rosenberg S A
A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(4):292-300.
1997: Kim C J; Prevette T; Cormier J; Overwijk W; Roden M; Restifo N P; Rosenberg S A; Marincola F M
Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(4):276-86.
1997: Shilyansky J; Yang J C; Custer M C; Spiess P; Mixon A; Cole D J; Mulé J J; Rosenberg S A; Nishimura M I
Identification of a T-cell receptor from a therapeutic murine T-cell clone.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(4):247-55.
1997: Robbins P F; El-Gamil M; Li Y F; Fitzgerald E B; Kawakami Y; Rosenberg S A
The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1997;159(1):303-8.
1997: Rosenberg S A
Cancer vaccines based on the identification of genes encoding cancer regression antigens.
Immunology today 1997;18(4):175-82.
1997: Bronte V; Carroll M W; Goletz T J; Wang M; Overwijk W W; Marincola F; Rosenberg S A; Moss B; Restifo N P
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(7):3183-8.
1997: Carroll M W; Overwijk W W; Chamberlain R S; Rosenberg S A; Moss B; Restifo N P
Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
Vaccine 1997;15(4):387-94.
1997: Kawakami Y; Battles J K; Kobayashi T; Ennis W; Wang X; Tupesis J P; Marincola F M; Robbins P F; Hearing V J; Gonda M A; Rosenberg S A
Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1.
Journal of immunological methods 1997;202(1):13-25.
1997: Irvine K R; Chamberlain R S; Shulman E P; Rosenberg S A; Restifo N P
Route of immunization and the therapeutic impact of recombinant anticancer vaccines.
Journal of the National Cancer Institute 1997;89(5):390-2.
1997: Bloom M B; Perry-Lalley D; Robbins P F; Li Y; el-Gamil M; Rosenberg S A; Yang J C
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.
The Journal of experimental medicine 1997;185(3):453-9.
1997: Zhai Y; Yang J C; Spiess P; Nishimura M I; Overwijk W W; Roberts B; Restifo N P; Rosenberg S A
Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(1):15-25.
1997: Cormier J N; Salgaller M L; Prevette T; Barracchini K C; Rivoltini L; Restifo N P; Rosenberg S A; Marincola F M
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
The cancer journal from Scientific American 1997;3(1):37-44.
1997: Kang X; Robbins P F; Fitzgerald E B; Wang R; Rosenberg S A; Kawakami Y
Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins.
Cancer research 1997;57(2):202-5.
1997: Kawakami Y; Rosenberg S A
Human tumor antigens recognized by T-cells.
Immunologic research 1997;16(4):313-39.
1997: Kawakami Y; Rosenberg S A
Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.
International reviews of immunology 1997;14(2-3):173-92.
1996: Alexander M; Salgaller M L; Celis E; Sette A; Barnes W A; Rosenberg S A; Steller M A
Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope.
American journal of obstetrics and gynecology 1996;175(6):1586-93.
1996: Wang R F; Appella E; Kawakami Y; Kang X; Rosenberg S A
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes.
The Journal of experimental medicine 1996;184(6):2207-16.
1996: Reeves M E; Royal R E; Lam J S; Rosenberg S A; Hwu P
Retroviral transduction of human dendritic cells with a tumor-associated antigen gene.
Cancer research 1996;56(24):5672-7.
1996: Rosenberg S A; Blaese R M; Brenner M K; Deisseroth A B; Ledley F D; Lotze M T; Wilson J M; Nabel G J; Cornetta K; Economou J S; Freeman S M; Riddell S R; Oldfield E; Gansbacher B; Dunbar C; Walker R E; Schuening F G; Roth J A; Crystal R G; Welsh M J; Culver K; Heslop H E; Simons J; Wilmott R W; Tiberghien P
Human gene marker/therapy clinical protocols.
Human gene therapy 1996;7(18):2287-313.
1996: Rosenberg S A
Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens.
Journal of the National Cancer Institute 1996;88(22):1635-44.
1996: Salgaller M L; Marincola F M; Cormier J N; Rosenberg S A
Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.
Cancer research 1996;56(20):4749-57.
1996: Dadmarz R D; Ordoubadi A; Mixon A; Thompson C O; Barracchini K C; Hijazi Y M; Steller M A; Rosenberg S A; Schwartzentruber D J
Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion.
The cancer journal from Scientific American 1996;2(5):263-72.
1996: Wang R F; Rosenberg S A
Human tumor antigens recognized by T lymphocytes: implications for cancer therapy.
Journal of leukocyte biology 1996;60(3):296-309.
1996: Parkhurst M R; Salgaller M L; Southwood S; Robbins P F; Sette A; Rosenberg S A; Kawakami Y
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(6):2539-48.
1996: Rosenberg S A; Blaese R M; Brenner M K; Deisseroth A B; Ledley F D; Lotze M T; Wilson J M; Nabel G J; Cornetta K; Economou J S; Freeman S M; Riddell S R; Oldfield E; Gansbacher B; Dunbar C; Walker R E; Schuening F G; Roth J A; Crystal R G; Welsh M J; Culver K; Heslop H E; Simons J; Wilmott R W; Aebischer P
Human gene marker/therapy clinical protocols.
Human gene therapy 1996;7(13):1621-47.
1996: Mulé J J; Custer M; Averbook B; Yang J C; Weber J S; Goeddel D V; Rosenberg S A; Schall T J
RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations.
Human gene therapy 1996;7(13):1545-53.
1996: Lam J S; Reeves M E; Cowherd R; Rosenberg S A; Hwu P
Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope.
Human gene therapy 1996;7(12):1415-22.
1996: Marincola F M; Rivoltini L; Salgaller M L; Player M; Rosenberg S A
Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(4):266-77.
1996: Kawakami Y; Robbins P F; Rosenberg S A
Human melanoma antigens recognized by T lymphocytes.
The Keio journal of medicine 1996;45(2):100-8.
1996: Chamberlain R S; Carroll M W; Bronte V; Hwu P; Warren S; Yang J C; Nishimura M; Moss B; Rosenberg S A; Restifo N P
Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.
Cancer research 1996;56(12):2832-6.
1996: Pass H I; Mew D J; Kranda K C; Temeck B K; Donington J S; Rosenberg S A
Isolated lung perfusion with tumor necrosis factor for pulmonary metastases.
The Annals of thoracic surgery 1996;61(6):1609-17.
1996: Marincola F M; Hijazi Y M; Fetsch P; Salgaller M L; Rivoltini L; Cormier J; Simonis T B; Duray P H; Herlyn M; Kawakami Y; Rosenberg S A
Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(3):192-205.
1996: Topalian S L; Gonzales M I; Parkhurst M; Li Y F; Southwood S; Sette A; Rosenberg S A; Robbins P F
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.
The Journal of experimental medicine 1996;183(5):1965-71.
1996: Rao J B; Chamberlain R S; Bronte V; Carroll M W; Irvine K R; Moss B; Rosenberg S A; Restifo N P
IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(9):3357-65.
1996: Royal R E; Steinberg S M; Krouse R S; Heywood G; White D E; Hwu P; Marincola F M; Parkinson D R; Schwartzentruber D J; Topalian S L; Yang J C; Rosenberg S A
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.
The cancer journal from Scientific American 1996;2(2):91-8.
1996: Robbins P F; El-Gamil M; Li Y F; Kawakami Y; Loftus D; Appella E; Rosenberg S A
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.
The Journal of experimental medicine 1996;183(3):1185-92.
1996: Wang R F; Parkhurst M R; Kawakami Y; Robbins P F; Rosenberg S A
Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.
The Journal of experimental medicine 1996;183(3):1131-40.
1996: Fraker D L; Alexander H R; Andrich M; Rosenberg S A
Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):479-89.
1996: Yannelli J R; Hyatt C; McConnell S; Hines K; Jacknin L; Parker L; Sanders M; Rosenberg S A
Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.
International journal of cancer. Journal international du cancer 1996;65(4):413-21.
1996: Rosenberg S A
Secrecy in medical research.
The New England journal of medicine 1996;334(6):392-4.
1996: Rosenberg S A; White D E
Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(1):81-4.
1996: Kim C J; Taubenberger J K; Simonis T B; White D E; Rosenberg S A; Marincola F M
Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(1):50-8.
1996: Bartels C J; Rosenberg S A; Yang J C
Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells.
Annals of surgical oncology 1996;3(1):67-73.
1996: Irvine K R; Rao J B; Rosenberg S A; Restifo N P
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(1):238-45.
1996: Chen P W; Wang M; Bronte V; Zhai Y; Rosenberg S A; Restifo N P
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(1):224-31.
1996: Zhai Y; Yang J C; Kawakami Y; Spiess P; Wadsworth S C; Cardoza L M; Couture L A; Smith A E; Rosenberg S A
Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(2):700-10.
1996: Restifo N P; Marincola F M; Kawakami Y; Taubenberger J; Yannelli J R; Rosenberg S A
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
Journal of the National Cancer Institute 1996;88(2):100-8.
1996: Kawakami Y; Rosenberg S A
T-cell recognition of self peptides as tumor rejection antigens.
Immunologic research 1996;15(3):179-90.
1996: Rosenberg S A; Kawakami Y; Robbins P F; Wang R
Identification of the genes encoding cancer antigens: implications for cancer immunotherapy.
Advances in cancer research 1996;70():145-77.
1996: Kawakami Y; Robbins P F; Wang R F; Rosenberg S A
Identification of tumor-regression antigens in melanoma.
Important advances in oncology 1996;():3-21.
1996: Walther M M; Jennings S B; Choyke P L; Andrich M; Hurley K; Linehan W M; Rosenberg S A; Alexander R B
Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma.
World journal of urology 1996;14 Suppl 1():S2-7.
1996: Moss B; Carroll M W; Wyatt L S; Bennink J R; Hirsch V M; Goldstein S; Elkins W R; Fuerst T R; Lifson J D; Piatak M; Restifo N P; Overwijk W; Chamberlain R; Rosenberg S A; Sutter G
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.
Advances in experimental medicine and biology 1996;397():7-13.
1996: Rosenberg S A
The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
Annual review of medicine 1996;47():481-91.
1995: Krouse R S; Royal R E; Heywood G; Weintraub B D; White D E; Steinberg S M; Rosenberg S A; Schwartzentruber D J
Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(4):272-8.
1995: Salgaller M L; Afshar A; Marincola F M; Rivoltini L; Kawakami Y; Rosenberg S A
Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
Cancer research 1995;55(21):4972-9.
1995: Wang M; Chen P W; Bronte V; Rosenberg S A; Restifo N P
Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(3):139-46.
1995: Blaese R M; Culver K W; Miller A D; Carter C S; Fleisher T; Clerici M; Shearer G; Chang L; Chiang Y; Tolstoshev P; Greenblatt J J; Rosenberg S A; Klein H; Berger M; Mullen C A; Ramsey W J; Muul L; Morgan R A; Anderson W F
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.
Science (New York, N.Y.) 1995;270(5235):475-80.
1995: Minamoto S; Treisman J; Hankins W D; Sugamura K; Rosenberg S A
Acquired erythropoietin responsiveness of interleukin-2-dependent T lymphocytes retrovirally transduced with genes encoding chimeric erythropoietin/interleukin-2 receptors.
Blood 1995;86(6):2281-7.
1995: Yang J C; Topalian S L; Schwartzentruber D J; Parkinson D R; Marincola F M; Weber J S; Seipp C A; White D E; Rosenberg S A
The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.
Cancer 1995;76(4):687-94.
1995: Markus N R; Rosenberg S A; Topalian S L
Analysis of cytokine secretion by melanoma-specific CD4+ T lymphocytes.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1995;15(8):739-46.
1995: Hwu P; Yang J C; Cowherd R; Treisman J; Shafer G E; Eshhar Z; Rosenberg S A
In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Cancer research 1995;55(15):3369-73.
1995: Kang X; Kawakami Y; el-Gamil M; Wang R; Sakaguchi K; Yannelli J R; Appella E; Rosenberg S A; Robbins P F
Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1995;155(3):1343-8.
1995: Fraker D L; Alexander H R; Andrich M; Rosenberg S A
Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
The cancer journal from Scientific American 1995;1(2):122-30.
1995: Rosenberg S A
The development of new cancer therapies based on the molecular identification of cancer regression antigens.
The cancer journal from Scientific American 1995;1(2):90-100.
1995: Rivoltini L; Barracchini K C; Viggiano V; Kawakami Y; Smith A; Mixon A; Restifo N P; Topalian S L; Simonis T B; Rosenberg S A
Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.
Cancer research 1995;55(14):3149-57.
1995: Robbins P F; el-Gamil M; Li Y F; Topalian S L; Rivoltini L; Sakaguchi K; Appella E; Kawakami Y; Rosenberg S A
Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(11):5944-50.
1995: Heywood G R; Rosenberg S A; Weber J S
Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2.
Journal of the National Cancer Institute 1995;87(12):915-22.
1995: Marincola F M; White D E; Wise A P; Rosenberg S A
Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1110-22.
1995: Bronte V; Tsung K; Rao J B; Chen P W; Wang M; Rosenberg S A; Restifo N P
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(10):5282-92.
1995: Wang M; Bronte V; Chen P W; Gritz L; Panicali D; Rosenberg S A; Restifo N P
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(9):4685-92.
1995: Irvine K R; McCabe B J; Rosenberg S A; Restifo N P
Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(9):4651-7.
1995: Restifo N P; Bacík I; Irvine K R; Yewdell J W; McCabe B J; Anderson R W; Eisenlohr L C; Rosenberg S A; Bennink J R
Antigen processing in vivo and the elicitation of primary CTL responses.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(9):4414-22.
1995: Jakobsen M K; Restifo N P; Cohen P A; Marincola F M; Cheshire L B; Linehan W M; Rosenberg S A; Alexander R B
Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;17(4):222-8.
1995: Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins P F; Sette A; Appella E; Rosenberg S A
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(8):3961-8.
1995: McCabe B J; Irvine K R; Nishimura M I; Yang J C; Spiess P J; Shulman E P; Rosenberg S A; Restifo N P
Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
Cancer research 1995;55(8):1741-7.
1995: MacFarlane M P; Yang J C; Guleria A S; White R L; Seipp C A; Einhorn J H; White D E; Rosenberg S A
The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma.
Cancer 1995;75(4):1030-7.
1995: Wang R F; Robbins P F; Kawakami Y; Kang X Q; Rosenberg S A
Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.
The Journal of experimental medicine 1995;181(2):799-804.
1995: Sgagias M K; Gagneton D C; Rosenberg S A; Danforth D N
Cellular characterization and retroviral transduction of short-term breast cancer cells.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;17(2):88-97.
1995: Cole D J; Weil D P; Shilyansky J; Custer M; Kawakami Y; Rosenberg S A; Nishimura M I
Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen.
Cancer research 1995;55(4):748-52.
1995: Dadmarz R; Sgagias M K; Rosenberg S A; Schwartzentruber D J
CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion.
Cancer immunology, immunotherapy : CII 1995;40(1):1-9.
1995: Stevens E J; Jacknin L; Robbins P F; Kawakami Y; el Gamil M; Rosenberg S A; Yannelli J R
Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(2):762-71.
1995: Treisman J; Hwu P; Minamoto S; Shafer G E; Cowherd R; Morgan R A; Rosenberg S A
Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen.
Blood 1995;85(1):139-45.
1995: Thom A K; Alexander H R; Andrich M P; Barker W C; Rosenberg S A; Fraker D L
Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(1):264-73.
1995: Alexander R B; Fitzgerald E B; Mixon A; Carter C S; Jakobsen M; Cohen P A; Rosenberg S A
Helper T cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;17(1):39-46.
1995: Yang J C; Fraker D L; Thom A K; Pass H I; Rosenberg S A
Isolation perfusion with tumor necrosis factor-alpha, interferon-gamma, and hyperthermia in the treatment of localized and metastatic cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1995;138():161-6.
1995: Ettinghausen S E; Rosenberg S A
Immunotherapy and gene therapy of cancer.
Advances in surgery 1995;28():223-54.
1994: White R L; Schwartzentruber D J; Guleria A; MacFarlane M P; White D E; Tucker E; Rosenberg S A
Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma.
Cancer 1994;74(12):3212-22.
1994: Cole D J; Weil D P; Shamamian P; Rivoltini L; Kawakami Y; Topalian S; Jennings C; Eliyahu S; Rosenberg S A; Nishimura M I
Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope.
Cancer research 1994;54(20):5265-8.
1994: Topalian S L; Rivoltini L; Mancini M; Markus N R; Robbins P F; Kawakami Y; Rosenberg S A
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(20):9461-5.
1994: Rosenberg S A
The gene therapy of cancer.
Preventive medicine 1994;23(5):624-6.
1994: Rosenberg S A; Yannelli J R; Yang J C; Topalian S L; Schwartzentruber D J; Weber J S; Parkinson D R; Seipp C A; Einhorn J H; White D E
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
Journal of the National Cancer Institute 1994;86(15):1159-66.
1994: Nishimura M I; Kawakami Y; Charmley P; O'Neil B; Shilyansky J; Yannelli J R; Rosenberg S A; Hood L
T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(2):85-94.
1994: Shamamian P; Mancini M; Kawakami Y; Restifo N P; Rosenberg S A; Topalian S L
Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.
Cancer immunology, immunotherapy : CII 1994;39(2):73-83.
1994: Salgaller M L; Weber J S; Koenig S; Yannelli J R; Rosenberg S A
Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.
Cancer immunology, immunotherapy : CII 1994;39(2):105-16.
1994: Minev B R; McFarland B J; Spiess P J; Rosenberg S A; Restifo N P
Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.
Cancer research 1994;54(15):4155-61.
1994: Kim H; Rosenberg S A; Steinberg S M; Cole D J; Weber J S
A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(1):60-5.
1994: Treisman J; Hwu P; Yannelli J R; Shafer G E; Cowherd R; Samid D; Rosenberg S A
Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid.
Cellular immunology 1994;156(2):448-57.
1994: Kawakami Y; Eliyahu S; Delgado C H; Robbins P F; Sakaguchi K; Appella E; Yannelli J R; Adema G J; Miki T; Rosenberg S A
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(14):6458-62.
1994: Schwartzentruber D J; Hom S S; Dadmarz R; White D E; Yannelli J R; Steinberg S M; Rosenberg S A; Topalian S L
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(7):1475-83.
1994: Topalian S L; Rivoltini L; Mancini M; Ng J; Hartzman R J; Rosenberg S A
Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
International journal of cancer. Journal international du cancer 1994;58(1):69-79.
1994: Kawakami Y; Eliyahu S; Sakaguchi K; Robbins P F; Rivoltini L; Yannelli J R; Appella E; Rosenberg S A
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
The Journal of experimental medicine 1994;180(1):347-52.
1994: Robbins P F; el-Gamil M; Kawakami Y; Stevens E; Yannelli J R; Rosenberg S A
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.
Cancer research 1994;54(12):3124-6.
1994: Pogrebniak H W; Witt C J; Terrill R; Kranda K; Travis W D; Rosenberg S A; Pass H I
Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials.
The Annals of thoracic surgery 1994;57(6):1477-83.
1994: Cole D J; Taubenberger J K; Pockaj B A; Yannelli J R; Carter C; Carrasquillo J; Leitman S; Steinberg S M; Rosenberg S A; Yang Y C
Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes.
Cancer immunology, immunotherapy : CII 1994;38(5):299-303.
1994: Hwu P; Rosenberg S A
The use of gene-modified tumor-infiltrating lymphocytes for cancer therapy.
Annals of the New York Academy of Sciences 1994;716():188-97; discussion 197-203.
1994: Weber J; Gunn H; Yang J; Parkinson D; Topalian S; Schwartzentruber D; Ettinghausen S; Levitt D; Rosenberg S A
A phase I trial of intravenous interleukin-6 in patients with advanced cancer.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;15(4):292-302.
1994: Kawakami Y; Eliyahu S; Delgado C H; Robbins P F; Rivoltini L; Topalian S L; Miki T; Rosenberg S A
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(9):3515-9.
1994: Marincola F M; Ettinghausen S; Cohen P A; Cheshire L B; Restifo N P; Mulé J J; Rosenberg S A
Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha.
Journal of immunology (Baltimore, Md. : 1950) 1994;152(7):3500-13.
1994: Weber J; Salgaller M; Samid D; Johnson B; Herlyn M; Lassam N; Treisman J; Rosenberg S A
Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
Cancer research 1994;54(7):1766-71.
1994: Pockaj B A; Sherry R M; Wei J P; Yannelli J R; Carter C S; Leitman S F; Carasquillo J A; Steinberg S M; Rosenberg S A; Yang J C
Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.
Cancer 1994;73(6):1731-7.
1994: Rosenberg S A; Yang J C; Topalian S L; Schwartzentruber D J; Weber J S; Parkinson D R; Seipp C A; Einhorn J H; White D E
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
JAMA : the journal of the American Medical Association 1994;271(12):907-13.
1994: Shilyansky J; Nishimura M I; Yannelli J R; Kawakami Y; Jacknin L S; Charmley P; Rosenberg S A
T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(7):2829-33.
1994: Marcus S G; Perry-Lalley D; Mulé J J; Rosenberg S A; Yang J C
The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;15(2):105-12.
1994: Cohen P A; Cohen P J; Rosenberg S A; Mulé J J
CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens.
Cancer research 1994;54(4):1055-8.
1994: Cohen P J; Cohen P A; Rosenberg S A; Katz S I; Mulé J J
Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells.
European journal of immunology 1994;24(2):315-9.
1994: Pockaj B A; Yang J C; Lotze M T; Lange J R; Spencer W F; Steinberg S M; Topalian S L; Schwartzentruber D J; White D E; Rosenberg S A
A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;15(1):22-8.
1994: Hwu P; Rosenberg S A
The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials.
Cancer detection and prevention 1994;18(1):43-50.
1994: Wang M G; Zakut R; Yi H; Rosenberg S; McBride O W
Localization of the MAGE1 gene encoding a human melanoma antigen to chromosome Xq28.
Cytogenetics and cell genetics 1994;67(2):116-9.
1994: Cohen P A; Fowler D H; Kim H; White R L; Czerniecki B J; Carter C; Gress R E; Rosenberg S A
Propagation of mouse and human T cells with defined antigen specificity and function.
Ciba Foundation symposium 1994;187():179-93; discussion 194-7.
1993: Marcus S G; Merino M J; Glatstein E; DeLaney T F; Steinberg S M; Rosenberg S A; Yang J C
Long-term outcome in 87 patients with low-grade soft-tissue sarcoma.
Archives of surgery (Chicago, Ill. : 1960) 1993;128(12):1336-43.
1993: Shiloni E; Karp S E; Custer M C; Shilyansky J; Restifo N P; Rosenberg S A; Mulé J J
Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.
Cancer immunology, immunotherapy : CII 1993;37(5):286-92.
1993: Restifo N P; Kawakami Y; Marincola F; Shamamian P; Taggarse A; Esquivel F; Rosenberg S A
Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(3):182-90.
1993: Rosenberg S A; Anderson W F; Blaese M; Hwu P; Yannelli J R; Yang J C; Topalian S L; Schwartzentruber D J; Weber J S; Ettinghausen S E
The development of gene therapy for the treatment of cancer.
Annals of surgery 1993;218(4):455-63; discussion 463-4.
1993: Cohen P A; Kim H; Fowler D H; Gress R E; Jakobsen M K; Alexander R B; Mulé J J; Carter C; Rosenberg S A
Use of interleukin-7, interleukin-2, and interferon-gamma to propagate CD4+ T cells in culture with maintained antigen specificity.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(3):242-52.
1993: Walther M M; Alexander R B; Weiss G H; Venzon D; Berman A; Pass H I; Linehan W M; Rosenberg S A
Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma.
Urology 1993;42(3):250-7; discussion 257-8.
1993: Schwartzentruber D J; Stetler-Stevenson M; Rosenberg S A; Topalian S L
Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation.
Blood 1993;82(4):1204-11.
1993: O'Neil B H; Kawakami Y; Restifo N P; Bennink J R; Yewdell J W; Rosenberg S A
Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(3):1410-8.
1993: Marcus S G; Choyke P L; Reiter R; Jaffe G S; Alexander R B; Linehan W M; Rosenberg S A; Walther M M
Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy.
The Journal of urology 1993;150(2 Pt 1):463-6.
1993: Kawakami Y; Nishimura M I; Restifo N P; Topalian S L; O'Neil B H; Shilyansky J; Yannelli J R; Rosenberg S A
T-cell recognition of human melanoma antigens.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(2):88-93.
1993: Ogasawara M; Rosenberg S A
Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Cancer research 1993;53(15):3561-8.
1993: Long J P; Walther M M; Alexander R B; Linehan W M; Rosenberg S A
The management of isolated renal recurrence of renal cell carcinoma following complete response to interleukin-2 based immunotherapy.
The Journal of urology 1993;150(1):176-8.
1993: Hwu P; Shafer G E; Treisman J; Schindler D G; Gross G; Cowherd R; Rosenberg S A; Eshhar Z
Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.
The Journal of experimental medicine 1993;178(1):361-6.
1993: Yannelli J R; Hyatt C; Johnson S; Hwu P; Rosenberg S A
Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor alpha (TNF-a) or interleukin-2 (IL-2).
Journal of immunological methods 1993;161(1):77-90.
1993: Marincola F M; Balkissoon J; Schwartzentruber D J; Hom S S; Concepcion R; Marcus S G; Yannelli J; Topalian S L; Parkinson D R; Rosenberg S A
Hemodynamic effects of the administration of tumor-infiltrating lymphocytes to cancer patients.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(4):282-8.
1993: Rosenberg S A; Lotze M T; Yang J C; Topalian S L; Chang A E; Schwartzentruber D J; Aebersold P; Leitman S; Linehan W M; Seipp C A
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
Journal of the National Cancer Institute 1993;85(8):622-32.
1993: Sindelar W F; Kinsella T J; Chen P W; DeLaney T F; Tepper J E; Rosenberg S A; Glatstein E
Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial.
Archives of surgery (Chicago, Ill. : 1960) 1993;128(4):402-10.
1993: Linehan W M; Walther M M; Alexander R B; Rosenberg S A
Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
Seminars in urology 1993;11(1):41-3.
1993: Averbook B J; Wei J P; Perry-Lalley D M; Rosenberg S A; Yang J C
A tumor-elaborated supernatant factor chemotactic for IL-2 expanded tumor infiltrating T-lymphocytes.
Lymphokine and cytokine research 1993;12(1):1-8.
1993: Restifo N P; Esquivel F; Kawakami Y; Yewdell J W; Mulé J J; Rosenberg S A; Bennink J R
Identification of human cancers deficient in antigen processing.
The Journal of experimental medicine 1993;177(2):265-72.
1993: Karp S E; Farber A; Salo J C; Hwu P; Jaffe G; Asher A L; Shiloni E; Restifo N P; Mulé J J; Rosenberg S A
Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor.
Journal of immunology (Baltimore, Md. : 1950) 1993;150(3):896-908.
1993: Hom S S; Schwartzentruber D J; Rosenberg S A; Topalian S L
Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(1):18-30.
1993: Sindelar W F; Kinsella T J; Tepper J E; DeLaney T F; Maher M M; Smith R; Rosenberg S A; Glatstein E
Randomized trial of intraoperative radiotherapy in carcinoma of the stomach.
American journal of surgery 1993;165(1):178-86; discussion 186-7.
1993: Pockaj B A; Topalian S L; Steinberg S M; White D E; Rosenberg S A
Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(1):136-47.
1993: Zakut R; Topalian S L; Kawakami Y; Mancini M; Eliyahu S; Rosenberg S A
Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines.
Cancer research 1993;53(1):5-8.
1993: Hom S S; Rosenberg S A; Topalian S L
Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion.
Cancer immunology, immunotherapy : CII 1993;36(1):1-8.
1993: Yang J C; Shlasko E; Ritchey J L; Landry J G; White D E; Rosenberg S A
Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):355-9.
1992: Marincola F M; Venzon D; White D; Rubin J T; Lotze M T; Simonis T B; Balkissoon J; Rosenberg S A; Parkinson D R
HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.
Cancer research 1992;52(23):6561-6.
1992: Lange J R; Raubitschek A A; Pockaj B A; Spencer W F; Lotze M T; Topalian S L; Yang J C; Rosenberg S A
A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(4):265-71.
1992: Rosenberg S A
Gene therapy for cancer.
JAMA : the journal of the American Medical Association 1992;268(17):2416-9.
1992: Topalian S L; Hom S S; Kawakami Y; Mancini M; Schwartzentruber D J; Zakut R; Rosenberg S A
Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(3):203-6.
1992: Mulé J J; Jicha D L; Rosenberg S A
The use of congenitally immunodeficient mice to study human tumor metastases and immunotherapy.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(3):196-8.
1992: Karp S E; Hwu P; Farber A; Restifo N P; Kriegler M; Mulé J J; Rosenberg S A
In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(6):2076-81.
1992: Mulé J J; Marcus S G; Yang J C; Weber J S; Rosenberg S A
Clinical application of IL6 in cancer therapy.
Research in immunology 1992;143(7):777-9.
1992: Sanda M G; Bolton E; Mulé J J; Rosenberg S A
In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(2):132-7.
1992: Schwartzentruber D J; Solomon D; Rosenberg S A; Topalian S L
Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(1):1-12.
1992: Pogrebniak H W; Haas G; Linehan W M; Rosenberg S A; Pass H I
Renal cell carcinoma: resection of solitary and multiple metastases.
The Annals of thoracic surgery 1992;54(1):33-8.
1992: Hwu P; Schwarz S; Custer M; Smith C A; Mulé J J; Rosenberg S A
Use of soluble recombinant TNF receptor to improve detection of TNF secretion in cultures of tumor infiltrating lymphocytes.
Journal of immunological methods 1992;151(1-2):139-47.
1992: Restifo N P; Spiess P J; Karp S E; Mulé J J; Rosenberg S A
A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.
The Journal of experimental medicine 1992;175(6):1423-31.
1992: Alexander R B; Bolton E S; Koenig S; Jones G M; Topalian S L; June C H; Rosenberg S A
Detection of antigen specific T lymphocytes by determination of intracellular calcium concentration using flow cytometry.
Journal of immunological methods 1992;148(1-2):131-41.
1992: Jicha D L; Schwarz S; Mulé J J; Rosenberg S A
Interleukin-7 mediates the generation and expansion of murine allosensitized and antitumor CTL.
Cellular immunology 1992;141(1):71-83.
1992: Sherry R M; Pass H I; Rosenberg S A; Yang J C
Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy.
Cancer 1992;69(7):1850-5.
1992: Choyke P L; Miller D L; Lotze M T; Whiteis J M; Ebbitt B; Rosenberg S A
Delayed reactions to contrast media after interleukin-2 immunotherapy.
Radiology 1992;183(1):111-4.
1992: Mulé J J; Custer M C; Travis W D; Rosenberg S A
Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice.
Journal of immunology (Baltimore, Md. : 1950) 1992;148(8):2622-9.
1992: Rosenberg S A
Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(2):180-99.
1992: Jicha D L; Yannelli J R; Custer M; Colandrea J; Taubenberger J; Mulé J J; Rosenberg S A
The persistence of human peripheral lymphocytes, tumor infiltrating lymphocytes, and colon adenocarcinomas in immunodeficient mice.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;11(1):19-29.
1992: Kawakami Y; Zakut R; Topalian S L; Stötter H; Rosenberg S A
Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.
Journal of immunology (Baltimore, Md. : 1950) 1992;148(2):638-43.
1992: Weber J S; Yang J C; Topalian S L; Schwartzentruber D J; White D E; Rosenberg S A
The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(1):33-40.
1991: Schwartzentruber D J; White D E; Zweig M H; Weintraub B D; Rosenberg S A
Thyroid dysfunction associated with immunotherapy for patients with cancer.
Cancer 1991;68(11):2384-90.
1991: Yang J C; Schwarz S L; Perry-Lalley D M; Rosenberg S A
Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.
Lymphokine and cytokine research 1991;10(6):475-80.
1991: Pockaj B A; Rosenberg S A
Lack of antihypertensive effect of interleukin-2 administration in humans.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(6):456-9.
1991: Alexander R B; Rosenberg S A
Adoptively transferred tumor-infiltrating lymphocytes can cure established metastatic tumor in mice and persist long-term in vivo as functional memory T lymphocytes.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(6):389-97.
1991: Jicha D L; Mulé J J; Rosenberg S A
Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy.
The Journal of experimental medicine 1991;174(6):1511-5.
1991: Stinson S F; DeLaney T F; Greenberg J; Yang J C; Lampert M H; Hicks J E; Venzon D; White D E; Rosenberg S A; Glatstein E J
Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma.
International journal of radiation oncology, biology, physics 1991;21(6):1493-9.
1991: Sherry R M; Rosenberg S A; Yang J C
Relapse after response to interleukin-2-based immunotherapy: patterns of progression and response to retreatment.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(5):371-5.
1991: Rosenberg S A
Immunotherapy and gene therapy of cancer.
Cancer research 1991;51(18 Suppl):5074s-5079s.
1991: Restifo N P; Esquivel F; Asher A L; Stötter H; Barth R J; Bennink J R; Mulé J J; Yewdell J W; Rosenberg S A
Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.
Journal of immunology (Baltimore, Md. : 1950) 1991;147(4):1453-9.
1991: Pogrebniak H W; Roth J A; Steinberg S M; Rosenberg S A; Pass H I
Reoperative pulmonary resection in patients with metastatic soft tissue sarcoma.
The Annals of thoracic surgery 1991;52(2):197-203.
1991: Aebersold P; Hyatt C; Johnson S; Hines K; Korcak L; Sanders M; Lotze M; Topalian S; Yang J; Rosenberg S A
Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.
Journal of the National Cancer Institute 1991;83(13):932-7.
1991: Barth R J; Mulé J J; Asher A L; Sanda M G; Rosenberg S A
Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-gamma and tumor necrosis factor.
Journal of immunological methods 1991;140(2):269-79.
1991: Hom S S; Topalian S L; Simonis T; Mancini M; Rosenberg S A
Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(3):153-64.
1991: Bock S N; Cameron R B; Kragel P; Mulé J J; Rosenberg S A
Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice.
Cancer research 1991;51(10):2649-54.
1991: Asher A L; Mulé J J; Kasid A; Restifo N P; Salo J C; Reichert C M; Jaffe G; Fendly B; Kriegler M; Rosenberg S A
Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(9):3227-34.
1991: Schwartzentruber D J; Topalian S L; Mancini M; Rosenberg S A
Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(10):3674-81.
1991: Wong R A; Alexander R B; Puri R K; Rosenberg S A
In vivo proliferation of adoptively transferred tumor-infiltrating lymphocytes in mice.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(2):120-30.
1991: Culver K; Cornetta K; Morgan R; Morecki S; Aebersold P; Kasid A; Lotze M; Rosenberg S A; Anderson W F; Blaese R M
Lymphocytes as cellular vehicles for gene therapy in mouse and man.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(8):3155-9.
1991: Mulé J J; Jicha D L; Aebersold P M; Travis W D; Rosenberg S A
Disseminated human malignant melanoma in congenitally immune-deficient (bg/nu/xid) mice.
Journal of the National Cancer Institute 1991;83(5):350-5.
1991: Barth R J; Mulé J J; Spiess P J; Rosenberg S A
Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.
The Journal of experimental medicine 1991;173(3):647-58.
1991: Karpati R M; Banks S M; Malissen B; Rosenberg S A; Sheard M A; Weber J S; Hodes R J
Phenotypic characterization of murine tumor-infiltrating T lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(6):2043-51.
1991: Lefor A T; Rosenberg S A
The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis.
The Journal of surgical research 1991;50(1):15-23.
1991: Morecki S; Karson E; Cornetta K; Kasid A; Aebersold P; Blaese R M; Anderson W F; Rosenberg S A
Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells.
Cancer immunology, immunotherapy : CII 1991;32(6):342-52.
1990: Kragel A H; Travis W D; Steis R G; Rosenberg S A; Roberts W C
Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer.
Cancer 1990;66(7):1513-6.
1990: Fox B A; Spiess P J; Kasid A; Puri R; Mulé J J; Weber J S; Rosenberg S A
In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes.
Journal of biological response modifiers 1990;9(5):499-511.
1990: Morecki S; Topalian S L; Myers W W; Okrongly D; Okarma T B; Rosenberg S A
Separation and growth of human CD4+ and CD8+ tumor-infiltrating lymphocytes and peripheral blood mononuclear cells by direct positive panning on covalently attached monoclonal antibody-coated flasks.
Journal of biological response modifiers 1990;9(5):463-74.
1990: Robertson C N; Linehan W M; Pass H I; Gomella L G; Haas G P; Berman A; Merino M; Rosenberg S A
Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.
The Journal of urology 1990;144(3):614-7; discussion 617-8.
1990: Alexander R B; Rosenberg S A
Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice.
Journal of immunology (Baltimore, Md. : 1950) 1990;145(5):1615-20.
1990: Skornick Y; Topalian S; Rosenberg S A
Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor.
Journal of biological response modifiers 1990;9(4):431-8.
1990: Rosenberg S A; Aebersold P; Cornetta K; Kasid A; Morgan R A; Moen R; Karson E M; Lotze M T; Yang J C; Topalian S L
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.
The New England journal of medicine 1990;323(9):570-8.
1990: Kasid A; Director E P; Stovroff M C; Lotze M T; Rosenberg S A
Cytokine regulation of tumor necrosis factor-alpha and -beta (lymphotoxin)-messenger RNA expression in human peripheral blood mononuclear cells.
Cancer research 1990;50(16):5072-6.
1990: Hauser G J; McIntosh J K; Travis W D; Rosenberg S A
Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy.
Cancer research 1990;50(12):3503-8.
1990: Lotze M T; Custer M C; Bolton E S; Wiebke E A; Kawakami Y; Rosenberg S A
Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications.
Human immunology 1990;28(2):198-207.
1990: Topalian S L; Kasid A; Rosenberg S A
Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(11):4487-95.
1990: Eisenthal A; Cameron R B; Rosenberg S A
Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(11):4463-71.
1990: Kragel A H; Travis W D; Feinberg L; Pittaluga S; Striker L M; Roberts W C; Lotze M T; Yang J J; Rosenberg S A
Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients.
Human pathology 1990;21(5):493-502.
1990: Rosenberg S A
Adoptive immunotherapy for cancer.
Scientific American 1990;262(5):62-9.
1990: Cleary M; Rosenberg S A
The bcl-2 gene, follicular lymphoma, and Hodgkin's disease.
Journal of the National Cancer Institute 1990;82(10):808-9.
1990: Jablons D; Bolton E; Mertins S; Rubin M; Pizzo P; Rosenberg S A; Lotze M T
IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(9):3630-6.
1990: Weber J S; Rosenberg S A
Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes.
Journal of the National Cancer Institute 1990;82(9):755-61.
1990: McIntosh J K; Mulé J J; Travis W D; Rosenberg S A
Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice.
Cancer research 1990;50(8):2463-9.
1990: Wiebke E A; Custer M C; Rosenberg S A; Lotze M T
Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Journal of biological response modifiers 1990;9(2):113-26.
1990: Yang J C; Perry-Lalley D; Rosenberg S A
An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity.
Journal of biological response modifiers 1990;9(2):149-59.
1990: Huang C M; Elin R J; Ruddel M; Sliva C; Lotze M T; Rosenberg S A
Changes in laboratory results for cancer patients treated with interleukin-2.
Clinical chemistry 1990;36(3):431-4.
1990: Mulé J J; McIntosh J K; Jablons D M; Rosenberg S A
Antitumor activity of recombinant interleukin 6 in mice.
The Journal of experimental medicine 1990;171(3):629-36.
1990: Barth R J; Bock S N; Mulé J J; Rosenberg S A
Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(4):1531-7.
1990: Topalian S L; Rosenberg S A
Cellular immunotherapy of cancer.
Critical care medicine 1990;18(2 Suppl):S144.
1990: Cameron R B; Spiess P J; Rosenberg S A
Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action.
The Journal of experimental medicine 1990;171(1):249-63.
1990: Haas G P; Solomon D; Rosenberg S A
Tumor-infiltrating lymphocytes from nonrenal urological malignancies.
Cancer immunology, immunotherapy : CII 1990;30(6):342-50.
1990: Belldegrun A; Kasid A; Uppenkamp M; Rosenberg S A
Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid.
Cancer immunology, immunotherapy : CII 1990;31(1):1-10.
1990: Aebersold P; Kasid A; Rosenberg S A
Selection of gene-marked tumor infiltrating lymphocytes from post-treatment biopsies: a case study.
Human gene therapy 1990;1(4):373-84.
1989: Rosenberg S A; Lotze M T; Yang J C; Linehan W M; Seipp C; Calabro S; Karp S E; Sherry R M; Steinberg S; White D E
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(12):1863-74.
1989: Fisher B; Keenan A M; Garra B S; Steinberg S M; White D E; DiBisceglie A M; Hoofnagle J H; Yolles P; Rosenberg S A; Lotze M T
Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(12):1852-62.
1989: Rubin J T; Elwood L J; Rosenberg S A; Lotze M T
Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
Cancer research 1989;49(24 Pt 1):7086-92.
1989: Eisenthal A; Rosenberg S A
Systemic induction of cells mediating antibody-dependent cellular cytotoxicity following administration of interleukin 2.
Cancer research 1989;49(24 Pt 1):6953-9.
1989: Griffith K D; Read E J; Carrasquillo J A; Carter C S; Yang J C; Fisher B; Aebersold P; Packard B S; Yu M Y; Rosenberg S A
In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma.
Journal of the National Cancer Institute 1989;81(22):1709-17.
1989: Rosenberg S A; Lotze M T; Yang J C; Aebersold P M; Linehan W M; Seipp C A; White D E
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.
Annals of surgery 1989;210(4):474-84; discussion 484-5.
1989: Saris S C; Patronas N J; Rosenberg S A; Alexander J T; Frank J; Schwartzentruber D J; Rubin J T; Barba D; Oldfield E H
The effect of intravenous interleukin-2 on brain water content.
Journal of neurosurgery 1989;71(2):169-74.
1989: Lack E E; Steinberg S M; White D E; Kinsella T; Glatstein E; Chang A E; Rosenberg S A
Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas.
Journal of surgical oncology 1989;41(4):263-73.
1989: Yang J C; Rosenberg S A
Surgery for adult patients with soft tissue sarcomas.
Seminars in oncology 1989;16(4):289-96.
1989: Krosnick J A; Mulé J J; McIntosh J K; Rosenberg S A
Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
Cancer research 1989;49(14):3729-33.
1989: Kasid A; Director E P; Rosenberg S A
Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(2):736-9.
1989: McIntosh J K; Jablons D M; Mulé J J; Nordan R P; Rudikoff S; Lotze M T; Rosenberg S A
In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(1):162-7.
1989: Belldegrun A; Kasid A; Uppenkamp M; Topalian S L; Rosenberg S A
Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(12):4520-6.
1989: Rosenberg S A
Clinical immunotherapy studies in the Surgery Branch of the U.S. National Cancer Institute: brief review.
Cancer treatment reviews 1989;16 Suppl A():115-21.
1989: Topalian S L; Solomon D; Rosenberg S A
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(10):3714-25.
1989: Jablons D; Steinberg S M; Roth J; Pittaluga S; Rosenberg S A; Pass H I
Metastasectomy for soft tissue sarcoma. Further evidence for efficacy and prognostic indicators.
The Journal of thoracic and cardiovascular surgery 1989;97(5):695-705.
1989: Kawakami Y; Custer M C; Rosenberg S A; Lotze M T
IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(10):3452-61.
1989: Eisenthal A; Rosenberg S A
The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(7):2307-13.
1989: McIntosh J K; Mulé J J; Krosnick J A; Rosenberg S A
Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
Cancer research 1989;49(6):1408-14.
1989: Belldegrun A; Webb D E; Austin H A; Steinberg S M; Linehan W M; Rosenberg S A
Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy.
The Journal of urology 1989;141(3):499-503.
1989: Jablons D M; Mulé J J; McIntosh J K; Sehgal P B; May L T; Huang C M; Rosenberg S A; Lotze M T
IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(5):1542-7.
1989: Stötter H; Wiebke E A; Tomita S; Belldegrun A; Topalian S; Rosenberg S A; Lotze M T
Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(5):1767-73.
1989: Puri R K; Travis W D; Rosenberg S A
Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo.
Cancer research 1989;49(4):969-76.
1989: Fisher B; Packard B S; Read E J; Carrasquillo J A; Carter C S; Topalian S L; Yang J C; Yolles P; Larson S M; Rosenberg S A
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(2):250-61.
1989: Barba D; Saris S C; Holder C; Rosenberg S A; Oldfield E H
Intratumoral LAK cell and interleukin-2 therapy of human gliomas.
Journal of neurosurgery 1989;70(2):175-82.
1989: Mulé J J; Krosnick J A; Rosenberg S A
IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(2):726-33.
1989: Lee R E; Lotze M T; Skibber J M; Tucker E; Bonow R O; Ognibene F P; Carrasquillo J A; Shelhamer J H; Parrillo J E; Rosenberg S A
Cardiorespiratory effects of immunotherapy with interleukin-2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(1):7-20.
1989: Fox B A; Rosenberg S A
Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.
Cancer immunology, immunotherapy : CII 1989;29(3):155-66.
1989: Asher A L; Mulé J J; Rosenberg S A
Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells.
Cancer immunology, immunotherapy : CII 1989;28(2):153-6.
1989: Chang A E; Rosenberg S A
Overview of interleukin-2 as an immunotherapeutic agent.
Seminars in surgical oncology 1989;5(6):385-90.
1989: Krosnick J A; McIntosh J K; Mulé J J; Rosenberg S A
Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor alpha in normal and tumor-bearing mice.
Cancer immunology, immunotherapy : CII 1989;30(3):133-8.
1989: Puri R K; Rosenberg S A
Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice.
Cancer immunology, immunotherapy : CII 1989;28(4):267-74.
1989: Mulé J J; Rosenberg S A
Immunotherapy with lymphokine combinations.
Important advances in oncology 1989;():99-126.
1988: Rosenberg S A; Packard B S; Aebersold P M; Solomon D; Topalian S L; Toy S T; Simon P; Lotze M T; Yang J C; Seipp C A
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
The New England journal of medicine 1988;319(25):1676-80.
1988: Kawakami Y; Rosenberg S A; Lotze M T
Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma.
The Journal of experimental medicine 1988;168(6):2183-91.
1988: Eisenthal A; Cameron R B; Uppenkamp I; Rosenberg S A
Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
Cancer research 1988;48(24 Pt 1):7140-5.
1988: Lee R E; Gaspari A A; Lotze M T; Chang A E; Rosenberg S A
Interleukin 2 and psoriasis.
Archives of dermatology 1988;124(12):1811-5.
1988: Schwartzentruber D; Lotze M T; Rosenberg S A
Colonic perforation. An unusual complication of therapy with high-dose interleukin-2.
Cancer 1988;62(11):2350-3.
1988: Rosenberg S A; Schwarz S L; Spiess P J
Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes.
Journal of the National Cancer Institute 1988;80(17):1393-7.
1988: Ognibene F P; Rosenberg S A; Lotze M; Skibber J; Parker M M; Shelhamer J H; Parrillo J E
Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.
Chest 1988;94(4):750-4.
1988: Cameron R B; McIntosh J K; Rosenberg S A
Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.
Cancer research 1988;48(20):5810-7.
1988: Weber J S; Rosenberg S A
Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro.
Cancer research 1988;48(20):5818-24.
1988: Eisenthal A; Rosenberg S A
Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma.
Clinical & experimental metastasis 1988;6(5):387-400.
1988: Webb D E; Austin H A; Belldegrun A; Vaughan E; Linehan W M; Rosenberg S A
Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.
Clinical nephrology 1988;30(3):141-5.
1988: Wiebke E A; Rosenberg S A; Lotze M T
Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(9):1440-9.
1988: Eisenthal A; Shiloni E; Rosenberg S A
Characterization of IL-2-induced murine cells which exhibit ADCC activity.
Cellular immunology 1988;115(2):257-72.
1988: Aebersold P; Carter C S; Hyatt C; Johnson S; Ottaway K; Leitman S F; Rosenberg S A
A simplified automated procedure for generation of human lymphokine-activated killer cells for use in clinical trials.
Journal of immunological methods 1988;112(1):1-7.
1988: Rosenberg S A
The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.
Annals of surgery 1988;208(2):121-35.
1988: McIntosh J K; Mulé J J; Merino M J; Rosenberg S A
Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
Cancer research 1988;48(14):4011-7.
1988: Saris S C; Rosenberg S A; Friedman R B; Rubin J T; Barba D; Oldfield E H
Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier.
Journal of neurosurgery 1988;69(1):29-34.
1988: Rosenberg S A; Lotze M T; Mulé J J
NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
Annals of internal medicine 1988;108(6):853-64.
1988: LeFor A T; Eisenthal A; Rosenberg S A
Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(11):4062-9.
1988: Simpson C; Seipp C A; Rosenberg S A
The current status and future applications of interleukin 2- and adoptive immunotherapy in cancer treatment.
Seminars in oncology nursing 1988;4(2):132-41.
1988: Ettinghausen S E; Puri R K; Rosenberg S A
Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice.
Journal of the National Cancer Institute 1988;80(3):177-88.
1988: Rosenberg S A
Cancer therapy with interleukin-2: immunologic manipulations can mediate the regression of cancer in humans.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(3):403-6.
1988: Lotze M T; Rosenberg S A
The immunologic treatment of cancer.
CA: a cancer journal for clinicians 1988;38(2):68-94.
1988: Rosenberg S A
Immunotherapy of cancer using interleukin 2: current status and future prospects.
Immunology today 1988;9(2):58-62.
1988: Tucker M A; Coleman C N; Cox R S; Varghese A; Rosenberg S A
Risk of second cancers after treatment for Hodgkin's disease.
The New England journal of medicine 1988;318(2):76-81.
1988: Kinsella T J; Sindelar W F; Lack E; Glatstein E; Rosenberg S A
Preliminary results of a randomized study of adjuvant radiation therapy in resectable adult retroperitoneal soft tissue sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(1):18-25.
1988: Belldegrun A; Uppenkamp I; Rosenberg S A
Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer.
The Journal of urology 1988;139(1):150-5.
1988: Belldegrun A; Muul L M; Rosenberg S A
Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Cancer research 1988;48(1):206-14.
1988: Papa M Z; Yang J C; Vetto J T; Shiloni E; Eisenthal A; Rosenberg S A
Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
Cancer research 1988;48(1):122-9.
1988: Carter C S; Leitman S F; Cullis H; Muul L M; Nason-Burchenal K; Rosenberg S A; Klein H G
Technical aspects of lymphokine-activated killer cell production.
Journal of clinical apheresis 1988;4(2-3):113-7.
1988: Mulé J J; Asher A; McIntosh J; Lafreniere R; Shiloni E; Lefor A; Reichert C M; Rosenberg S A
Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: tumor size influences the response to therapy.
Cancer immunology, immunotherapy : CII 1988;26(3):202-8.
1988: Rosenberg S A
Development of new immunologic approaches to cancer therapy.
Blood purification 1988;6(2):69-76.
1988: Yang J C; Rosenberg S A
Current approaches to the adoptive immunotherapy of cancer.
Advances in experimental medicine and biology 1988;233():459-67.
1988: Mulé J J; Schwarz S L; Roberts A B; Sporn M B; Rosenberg S A
Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.
Cancer immunology, immunotherapy : CII 1988;26(2):95-100.
1987: Muul L M; Nason-Burchenal K; Hyatt C; Schwarz S; Slavin D; Director E P; Rosenberg S A
Studies of serum-free culture medium in the generation of lymphokine activated killer cells.
Journal of immunological methods 1987;105(2):183-92.
1987: Weber J S; Jay G; Tanaka K; Rosenberg S A
Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection.
The Journal of experimental medicine 1987;166(6):1716-33.
1987: Spiess P J; Yang J C; Rosenberg S A
In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
Journal of the National Cancer Institute 1987;79(5):1067-75.
1987: Cohen P J; Lotze M T; Roberts J R; Rosenberg S A; Jaffe E S
The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression.
The American journal of pathology 1987;129(2):208-16.
1987: Skibber J M; Lotze M T; Seipp C A; Salcedo R; Rosenberg S A
Limb-sparing surgery for soft tissue sarcomas: wound related morbidity in patients undergoing wide local excision.
Surgery 1987;102(3):447-52.
1987: Mulé J J; Smith C A; Rosenberg S A
Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.
The Journal of experimental medicine 1987;166(3):792-7.
1987: Denicoff K D; Rubinow D R; Papa M Z; Simpson C; Seipp C A; Lotze M T; Chang A E; Rosenstein D; Rosenberg S A
The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.
Annals of internal medicine 1987;107(3):293-300.
1987: Gaspari A A; Lotze M T; Rosenberg S A; Stern J B; Katz S I
Dermatologic changes associated with interleukin 2 administration.
JAMA : the journal of the American Medical Association 1987;258(12):1624-9.
1987: Muul L M; Nason-Burchenal K; Carter C S; Cullis H; Slavin D; Hyatt C; Director E P; Leitman S F; Klein H G; Rosenberg S A
Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy.
Journal of immunological methods 1987;101(2):171-81.
1987: Carter C S; Leitman S F; Cullis H; Muul L M; Nason-Burchenal K; Rosenberg S A; Klein H G
Use of a continuous-flow cell separator in density gradient isolation of lymphocytes.
Transfusion 1987;27(4):362-5.
1987: Mulé J J; Yang J C; Afreniere R L; Shu S Y; Rosenberg S A
Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(1):285-94.
1987: Shu S Y; Chou T; Rosenberg S A
Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(1):295-304.
1987: Ettinghausen S E; Moore J G; White D E; Platanias L; Young N S; Rosenberg S A
Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.
Blood 1987;69(6):1654-60.
1987: Belldegrun A; Webb D E; Austin H A; Steinberg S M; White D E; Linehan W M; Rosenberg S A
Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.
Annals of internal medicine 1987;106(6):817-22.
1987: Eisenthal A; Lafreniere R; Lefor A T; Rosenberg S A
Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.
Cancer research 1987;47(11):2771-6.
1987: Skibber J M; Lotze M T; Uppenkamp I; Ross W; Rosenberg S A
Identification and expansion of human lymphokine-activated killer cells: implications for the immunotherapy of cancer.
The Journal of surgical research 1987;42(6):613-21.
1987: Lotze M T; Roberts K; Custer M C; Segal D A; Rosenberg S A
Specific binding and lysis of human melanoma by IL-2-activated cells coated with anti-T3 or anti-Fc receptor cross-linked to antimelanoma antibody: a possible approach to the immunotherapy of human tumors.
The Journal of surgical research 1987;42(5):580-9.
1987: Rosenberg S A; Lotze M T; Muul L M; Chang A E; Avis F P; Leitman S; Linehan W M; Robertson C N; Lee R E; Rubin J T
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
The New England journal of medicine 1987;316(15):889-97.
1987: Lotze M T; Custer M C; Sharrow S O; Rubin L A; Nelson D L; Rosenberg S A
In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration.
Cancer research 1987;47(8):2188-95.
1987: Vetto J T; Papa M Z; Lotze M T; Chang A E; Rosenberg S A
Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(3):496-503.
1987: Shiloni E; Eisenthal A; Sachs D; Rosenberg S A
Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(6):1992-8.
1987: Shu S; Chou T; Rosenberg S A
In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice.
Cancer research 1987;47(5):1354-60.
1987: Asher A; Mulé J J; Reichert C M; Shiloni E; Rosenberg S A
Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(3):963-74.
1987: Muul L M; Spiess P J; Director E P; Rosenberg S A
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.
Journal of immunology (Baltimore, Md. : 1950) 1987;138(3):989-95.
1987: Mulé J J; Rosenberg S A
Mechanistic aspects of successful immunotherapy of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2.
Progress in clinical and biological research 1987;244():79-91.
1987: Topalian S L; Rosenberg S A
Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.
Acta haematologica 1987;78 Suppl 1():75-6.
1987: Skibber J M; Lotze M T; Muul L M; Uppenkamp I K; Ross W; Rosenberg S A
Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell.
Natural immunity and cell growth regulation 1987;6(6):291-305.
1986: Ettinghausen S E; Bonow R O; Palmeri S T; Seipp C A; Steinberg S M; White D E; Rosenberg S A
Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas.
Archives of surgery (Chicago, Ill. : 1960) 1986;121(12):1445-51.
1986: Lotze M T; Custer M C; Rosenberg S A
Intraperitoneal administration of interleukin-2 in patients with cancer.
Archives of surgery (Chicago, Ill. : 1960) 1986;121(12):1373-9.
1986: Lotze M T; Chang A E; Seipp C A; Simpson C; Vetto J T; Rosenberg S A
High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings.
JAMA : the journal of the American Medical Association 1986;256(22):3117-24.
1986: Lotze M T; Matory Y L; Rayner A A; Ettinghausen S E; Vetto J T; Seipp C A; Rosenberg S A
Clinical effects and toxicity of interleukin-2 in patients with cancer.
Cancer 1986;58(12):2764-72.
1986: Rizzoni W E; Pass H I; Wesley M N; Rosenberg S A; Roth J A
Resection of recurrent pulmonary metastases in patients with soft-tissue sarcomas.
Archives of surgery (Chicago, Ill. : 1960) 1986;121(11):1248-52.
1986: Seipp C A; Simpson C; Rosenberg S A
Clinical trials with IL-2.
Oncology nursing forum 1986;13(6):25-9.
1986: Shiloni E; Lafreniere R; Mulé J J; Schwarz S L; Rosenberg S A
Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Cancer research 1986;46(11):5633-40.
1986: Papa M Z; Vetto J T; Ettinghausen S E; Mulé J J; Rosenberg S A
Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.
Cancer research 1986;46(11):5618-23.
1986: Lafreniere R; Rosenstein M S; Rosenberg S A
Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo.
Journal of immunological methods 1986;94(1-2):37-49.
1986: Henkart P A; Yue C C; Yang J; Rosenberg S A
Cytolytic and biochemical properties of cytoplasmic granules of murine lymphokine-activated killer cells.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(8):2611-7.
1986: Papa M Z; Mulé J J; Rosenberg S A
Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Cancer research 1986;46(10):4973-8.
1986: Rosenstein M; Ettinghausen S E; Rosenberg S A
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(5):1735-42.
1986: Rosenberg S A; Spiess P; Lafreniere R
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
Science (New York, N.Y.) 1986;233(4770):1318-21.
1986: Lotze M T; Rosenberg S A
Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.
Immunobiology 1986;172(3-5):420-37.
1986: Rosenberg S A; Lotze M T; Muul L M; Leitman S; Chang A E; Vetto J T; Seipp C A; Simpson C
A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.
Surgery 1986;100(2):262-72.
1986: Chang A E; Shu S Y; Chou T; Lafreniere R; Rosenberg S A
Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors.
Cancer research 1986;46(7):3426-30.
1986: Yang J C; Mulé J J; Rosenberg S A
Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
Journal of immunology (Baltimore, Md. : 1950) 1986;137(2):715-22.
1986: Rosenberg S A
The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2.
Seminars in oncology 1986;13(2):200-6.
1986: Ettinghausen S E; Rosenberg S A
Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Cancer research 1986;46(6):2784-92.
1986: Danforth D N; Findlay P A; McDonald H D; Lippman M E; Reichert C M; d'Angelo T; Gorrell C R; Gerber N L; Lichter A S; Rosenberg S A
Complete axillary lymph node dissection for stage I-II carcinoma of the breast.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(5):655-62.
1986: Shu S; Chou T; Rosenberg S A
In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
Journal of immunology (Baltimore, Md. : 1950) 1986;136(10):3891-8.
1986: Mulé J J; Yang J; Shu S; Rosenberg S A
The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Journal of immunology (Baltimore, Md. : 1950) 1986;136(10):3899-909.
1986: Matis L A; Shu S; Groves E S; Zinn S; Chou T; Kruisbeek A M; Rosenstein M; Rosenberg S A
Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression.
Journal of immunology (Baltimore, Md. : 1950) 1986;136(9):3496-501.
1986: Muul L M; Director E P; Hyatt C L; Rosenberg S A
Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy.
Journal of immunological methods 1986;88(2):265-75.
1986: Lafreniere R; Rosenberg S A
A novel approach to the generation and identification of experimental hepatic metastases in a murine model.
Journal of the National Cancer Institute 1986;76(2):309-22.
1986: Mulé J J; Ettinghausen S E; Spiess P J; Shu S; Rosenberg S A
Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Cancer research 1986;46(2):676-83.
1986: Lotze M T; Rosenberg S A
Protocol design for lymphokine testing in clinical studies of human cancer.
Lymphokine research 1986;5 Suppl 1():S177-81.
1986: Ettinghausen S E; Rosenberg S A
The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Springer seminars in immunopathology 1986;9(1):51-71.
1986: Rosenberg S A; Lotze M T
Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
Annual review of immunology 1986;4():681-709.
1985: Rosenberg S A; Lotze M T; Muul L M; Leitman S; Chang A E; Ettinghausen S E; Matory Y L; Skibber J M; Shiloni E; Vetto J T
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
The New England journal of medicine 1985;313(23):1485-92.
1985: Lafreniere R; Rosenberg S A
Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(6):4273-80.
1985: Ettinghausen S E; Lipford E H; Mulé J J; Rosenberg S A
Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(5):3623-35.
1985: Lotze M T; Matory Y L; Ettinghausen S E; Rayner A A; Sharrow S O; Seipp C A; Custer M C; Rosenberg S A
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(4):2865-75.
1985: Shu S; Rosenberg S A
Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(4):2895-903.
1985: Rosenberg S A; Mulé J J
Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Surgery 1985;98(3):437-44.
1985: Lafreniere R; Rosenberg S A
Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Cancer research 1985;45(8):3735-41.
1985: Ettinghausen S E; Lipford E H; Mulé J J; Rosenberg S A
Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(2):1488-97.
1985: Kawamura H; Rosenberg S A; Berzofsky J A
Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness.
The Journal of experimental medicine 1985;162(1):381-6.
1985: Mulé J J; Shu S; Rosenberg S A
The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Journal of immunology (Baltimore, Md. : 1950) 1985;135(1):646-52.
1985: Rosenberg S A; Seipp C A; White D E; Wesley R
Perioperative blood transfusions are associated with increased rates of recurrence and decreased survival in patients with high-grade soft-tissue sarcomas of the extremities.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(5):698-709.
1985: Rosenberg S A; Mulé J J; Spiess P J; Reichert C M; Schwarz S L
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
The Journal of experimental medicine 1985;161(5):1169-88.
1985: Reichert C M; Rosenstein M; Von Glatz J; Hsu S M; Rosenberg S A
Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
Laboratory investigation; a journal of technical methods and pathology 1985;52(3):304-13.
1985: Rosenberg S A
Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1985;3(3):299-310.
1985: Rayner A A; Grimm E A; Lotze M T; Chu E W; Rosenberg S A
Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
Cancer 1985;55(6):1327-33.
1985: Rosenberg S A
The changing approach to cancer surgery.
Hospital practice (Office ed.) 1985;20(3):105-7, 113, 116-7 passim.
1985: Mulé J J; Rosenstein M; Shu S; Rosenberg S A
Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s).
Cancer research 1985;45(2):526-31.
1985: Lotze M T; Frana L W; Sharrow S O; Robb R J; Rosenberg S A
In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
Journal of immunology (Baltimore, Md. : 1950) 1985;134(1):157-66.
1985: Chang A E; Lotze M T; Ames R S; Roth J A; Rosenberg S A
A large scale method of separating multiple lymphokines secreted by the murine EL-4 thymoma.
Journal of immunopharmacology 1985;7(1):17-31.
1984: Kaufmann Y; Chang A E; Robb R J; Rosenberg S A
Mechanism of action of Cyclosporin A: inhibition of lymphokine secretion studied with antigen-stimulated T cell hybridomas.
Journal of immunology (Baltimore, Md. : 1950) 1984;133(6):3107-11.
1984: Rosenberg S A
Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Journal of biological response modifiers 1984;3(5):501-11.
1984: Lotze M T; Robb R J; Sharrow S O; Frana L W; Rosenberg S A
Systemic administration of interleukin-2 in humans.
Journal of biological response modifiers 1984;3(5):475-82.
1984: Mulé J J; Shu S; Schwarz S L; Rosenberg S A
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.
Science (New York, N.Y.) 1984;225(4669):1487-9.
1984: Kaufmann Y; Rosenberg S A
Blocking by cyclosporine of antigen-induced maturation and lymphokine secretion by cytotoxic T lymphocyte hybridomas.
Transplantation 1984;38(2):148-51.
1984: Rosenberg S A
The organization of surgical oncology in university departments of surgery.
Surgery 1984;95(5):632-4.
1984: Rosenstein M; Rosenberg S A
Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies.
Journal of the National Cancer Institute 1984;72(5):1161-5.
1984: Rosenstein M; Yron I; Kaufmann Y; Rosenberg S A
Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
Cancer research 1984;44(5):1946-53.
1984: Donohue J H; Lotze M T; Robb R J; Rosenstein M; Braziel R M; Jaffe E S; Rosenberg S A
In vivo administration of purified Jurkat-derived interleukin 2 in mice.
Cancer research 1984;44(4):1380-6.
1984: Donohue J H; Rosenstein M; Chang A E; Lotze M T; Robb R J; Rosenberg S A
The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
Journal of immunology (Baltimore, Md. : 1950) 1984;132(4):2123-8.
1984: Rosenberg S A; Grimm E A; McGrogan M; Doyle M; Kawasaki E; Koths K; Mark D F
Biological activity of recombinant human interleukin-2 produced in Escherichia coli.
Science (New York, N.Y.) 1984;223(4643):1412-4.
1984: Mazumder A; Rosenberg S A
Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
The Journal of experimental medicine 1984;159(2):495-507.
1984: Rosenberg S A
Adoptive immunotherapy of cancer: accomplishments and prospects.
Cancer treatment reports 1984;68(1):233-55.
1984: Grimm E A; Vose B M; Chu E W; Wilson D J; Lotze M T; Rayner A A; Rosenberg S A
The human mixed lymphocyte-tumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissues.
Cancer immunology, immunotherapy : CII 1984;17(2):83-9.
1983: Castellino R A; Dunnick N R; Goffinet D R; Rosenberg S R; Kaplan H S
Predictive value of lymphography for sites of subdiaphragmatic disease encountered at staging laparotomy in newly diagnosed Hodgkin's disease and non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1983;1(9):532-6.
1983: Rosenberg S A; Spiess P J; Schwarz S
In vivo administration of Interleukin-2 enhances specific alloimmune responses.
Transplantation 1983;35(6):631-4.
1983: Mazumder A; Grimm E A; Rosenberg S A
Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin.
Journal of immunology (Baltimore, Md. : 1950) 1983;130(2):958-64.
1983: Mazumder A; Grimm E A; Rosenberg S A
Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization.
Cancer immunology, immunotherapy : CII 1983;15(1):1-10.
1982: Rosenberg S A; Eberlein T J; Grimm E A; Lotze M T; Mazumder A; Rosenstein M
Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer.
Surgery 1982;92(2):328-36.
1982: Eberlein T J; Rosenstein M; Spiess P J; Rosenberg S A
Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
Journal of the National Cancer Institute 1982;69(1):109-16.
1982: Brown J M; Shoffner P C; Tondreau S P; Matthews E J; Terry W D; Rosenberg S A
Cytotoxic antibody reactivity in sera of melanoma patients against allogeneic and autologous cultured tumor cells and fibroblasts.
Cancer research 1982;42(6):2216-22.
1982: Eberlein T J; Rosenstein M; Spiess P; Wesley R; Rosenberg S A
Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor.
Cancer immunology, immunotherapy : CII 1982;13(1):5-13.
1981: Lotze M T; Grimm E A; Mazumder A; Strausser J L; Rosenberg S A
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.
Cancer research 1981;41(11 Pt 1):4420-5.
1981: Lotze M T; Rosenberg S A
In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity.
Journal of immunology (Baltimore, Md. : 1950) 1981;126(6):2215-20.
1981: Rosenberg S A
Treatment of soft tissue and bone sarcomas: review of studies at the National Cancer Institute.
National Cancer Institute monograph 1981;(56):241-4.
1981: Lotze M T; Duncan M A; Gerber L H; Woltering E A; Rosenberg S A
Early versus delayed shoulder motion following axillary dissection: a randomized prospective study.
Annals of surgery 1981;193(3):288-95.
1981: Spiess P J; Rosenberg S A
A simplified method for the production of murine T-cell growth factor free of lectin.
Journal of immunological methods 1981;42(2):213-22.
1980: Lotze M T; Line B R; Mathisen D J; Rosenberg S A
The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.
Journal of immunology (Baltimore, Md. : 1950) 1980;125(4):1487-93.
1980: Austin E H; Brennan M F; Rosenberg S A
Effects of protein-calorie restriction on the immune response to skin allografts in the rat.
Transplantation 1980;30(3):219-25.
1980: Rosenberg S A; Spiess P J; Schwarz S
In vitro growth of murine T cells. IV. Use of T-cell growth factor to clone lymphoid cells.
Cellular immunology 1980;54(2):293-306.
1980: Yron I; Wood T A; Spiess P J; Rosenberg S A
In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.
Journal of immunology (Baltimore, Md. : 1950) 1980;125(1):238-45.
1980: Lotze M T; Strausser J L; Rosenberg S A
In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells.
Journal of immunology (Baltimore, Md. : 1950) 1980;124(6):2972-8.
1975: Cohen M H; Schour L; Felix E L; Bernstein A D; Chretien P B; Rosenberg S A; Ketcham A S
Staging laparotomy in the treatment of metastatic melanoma of the lower extremities.
Annals of surgery 1975;182(6):710-4.
1975: Rosenberg S A; Dorfman R F; Kaplan H S
A summary of the results of a review of 405 patients with non-Hodgkin's lymphoma at Stanford University.
The British journal of cancer. Supplement 1975;2():168-73.
1974: Wilson R E; Alexander P; Rosenberg S A; Simmons R L
Horizons in tumor immunology. A seminar.
Archives of surgery (Chicago, Ill. : 1960) 1974;109(1):17-29.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

STEVEN ROSENBERG

Research Profile (preview)

Chemicals & Drugs

Disorders

Anatomy

Living Beings

Procedures

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of STEVEN ROSENBERG (preview)

All Publications